

Anesthesiology  
 1999; 90:576-99  
 © 1999 American Society of Anesthesiologists, Inc.  
 Lippincott Williams & Wilkins, Inc.

## *A Review of the Use of Fentanyl Analgesia in the Management of Acute Pain in Adults*

Philip W. H. Peng, M.B.B.S., F.R.C.P.C.,\* Alan N. Sandler, M.B.Ch.B., M.Sc., F.R.C.P.C.†

FENTANYL was one of a series of opioids synthesized by Janssen Pharmaceutica in the 1950s and 1960s in an effort to produce opioid analgesics with enhanced analgesic activity and potency and fewer adverse effects compared with morphine or meperidine.<sup>1,2</sup> It was first used clinically as a component of neuroleptanalgesia in combination with the butyrophenone, droperidol.<sup>3</sup> Between 1975 and 1981, fentanyl was adopted widely as a potent intraoperative analgesic agent with relatively few adverse effects. In small-to-moderate bolus doses (3 to 5  $\mu\text{g}/\text{kg}$ ), it combined with different intravenous supplements to produce "balanced" anesthesia,<sup>4</sup> whereas large doses (as much as 100  $\mu\text{g}/\text{kg}$ ) were used to induce and to maintain anesthesia in critically ill patients and those undergoing cardiopulmonary bypass procedures.<sup>5</sup>

Fentanyl's popularity as an intraoperative agent relates directly to the cardiovascular stability it provides, even in critically ill patients.<sup>6,7</sup> But its analgesic efficacy relative to the intensity of side effects prompted much interest in its use as an analgesic agent after operation or in the intensive care unit. Investigators began by exploring alternatives to the traditional intramuscular or intravenous routes for postoperative administration to optimize the potential clinical benefits of fentanyl's physiochemical properties. This article reviews the liter-

ature related to the use of fentanyl as an analgesic in the postoperative period and in patients in the intensive care unit, and it evaluates the pharmacokinetics, pharmacodynamics, efficacy, and limitations of existing and experimental routes of administration.

### Physical and Chemical Properties of Fentanyl

Fentanyl, N-(1-phenethyl-4-piperidyl) propionanilide, is structurally related to meperidine. Commercially, fentanyl is formulated as a citrate, available in a water-soluble, white crystalline powder that requires no preservatives. It has a molecular weight of 528.29 and a melting point of 148.5 to 150°C. Each milliliter of aqueous solution contains a base of 0.05 mg fentanyl (0.0785 mg of the citrate).

The negative logarithm of the acid ionization constant of fentanyl (pKa) is 8.43. At physiologic pH, 8.5% of the compound is un-ionized in plasma and 84% is bound to erythrocytes,  $\alpha_1$ -acid glycoprotein, and plasma albumin.<sup>8</sup> The octanol-water partition coefficient at physiologic pH is 816 for fentanyl compared with 1.4 for morphine. Therefore, fentanyl is highly lipophilic, whereas morphine is hydrophilic. Multiplying this partition coefficient by the plasma-free fraction (table 1) yields a relative potential to enter the central nervous system that is approximately 133 times larger than that of morphine.<sup>9</sup>

Optimization of the molecular configuration of fentanyl increased its potency. Fentanyl is 100 to 300 times more potent than morphine per dose, depending on the animal species.<sup>10-12</sup> This greater dose potency permits a low therapeutic blood concentration of approximately 0.6 to 3 ng/ml for analgesia. This, in turn, necessitates a sensitive method of assay.

Radioimmunoassay and gas liquid chromatography are the two most common methods used. The current radioimmunoassay method can measure plasma fentanyl concentrations as low as 0.06 ng/ml and was first reported in 1977.<sup>13</sup> The standard curves are linear for a concentration range of 0.06-20 ng/ml, and the coefficient of variation of the assay ranges from 1-12%.<sup>14-21</sup>

\* Staff Anaesthetist, Department of Anaesthesia, The Toronto Hospital and Mount Sinai Hospital; Assistant Professor, University of Toronto.

† Anaesthetist-in-Chief, The Toronto Hospital and Mount Sinai Hospital; Professor, University of Toronto.

Received from the Department of Anaesthesia, The Toronto Hospital and Mount Sinai Hospital, and The Department of Anaesthesia, University of Toronto, Toronto, Ontario, Canada. Submitted for publication December 4, 1996. Accepted for publication September 9, 1998. Support was provided by the Department of Anaesthesia Research Fund, The Toronto Hospital and Mount Sinai Hospital, from the Department of Anaesthesia, University of Toronto, and from Janssen-Ortho, Inc.

Address reprint requests to Dr. Sandler: Department of Anaesthesia, The Toronto Hospital, Bell Wing 4-644, 585 University Avenue, Toronto, Ontario, Canada, M5G 2C4. Address electronic mail to: asandler@torhosp.toronto.on.ca

Key words: Analgesia; fentanyl; pharmacodynamic; pharmacokinetics.

## FENTANYL AND ACUTE PAIN MANAGEMENT

**Table 1. Pharmacology Comparison between Fentanyl and Morphine in Adults**

	Morphine	Fentanyl
Rapid distribution half-life ( $t_{1/2 \pi}$ , min)	1.2–2.5	1.0–1.7
Slow distribution half-life ( $t_{1/2 \alpha}$ , min)	9–13.3	13–28
Elimination half-life ( $t_{1/2 \beta}$ , h)	1.7–2.2	3.1–7.9
Blood-brain equilibration half-life ( $t_{1/2 k_{eo}}$ , min)	15–20	6.6
Volume of distribution, steady state (L/kg)	3.2–3.4	3.2–5.9
Clearance* ( $\text{ml} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ )	15–23	8–21
$pK_a$	7.93	8.43
% unionized at pH 7.4	23	8.5
Octanol: H <sub>2</sub> O partition coefficient	1.4	816
% unbound drug at pH 7.4	70	16
Relative CNS penetrability†	1	133

\* Calculated from blood level measured in plasma.

† Apparent octanol: H<sub>2</sub>O partition coefficient at pH 7.4 multiplied by the free fraction of drug in plasma and divided by the value (0.98) for morphine gives the relative potential of the drug to enter the CNS.

Adapted and modified from Murphy,<sup>189</sup> Hug,<sup>9</sup> with permission;  $t_{1/2 k_{eo}}$  data from Inturrisi,<sup>190</sup> Scott.<sup>32</sup>

However, radioimmunoassay analysis can overestimate plasma fentanyl concentrations (fentanyl  $C_p$ ) by as much as 29 to 100%,<sup>22</sup> limiting reliability, and thereby contributing to the observed differences in the pharmacokinetic data reported for fentanyl.<sup>22</sup>

Assay by gas liquid chromatography using either flame-ionization, nitrogen phosphorus, or mass spectrometric detection is sensitive and reproducible. With nitrogen phosphorus,<sup>23</sup> the mean coefficient of variation for concentrations ranging from 0.25–10 ng/ml is 4.65%; with mass spectrometric detection, the mean coefficient of variation is 6.9% for a range of 0.2–68 ng/ml.<sup>24</sup> When compared directly with the radioimmunoassay method, the gas liquid chromatography–nitrogen phosphorus method results in comparable values in the spiked control and patient samples.<sup>25</sup> At the detection limit of 0.25 ng/ml, gas liquid chromatography has a coefficient of variation of 14.7%, comparable to 14.2% for radioimmunoassay. At higher concentrations, the coefficient of variation decreases to approximately 5%. This increased variability at the detection limit significantly affects pharmacokinetic analysis, because the terminal half-life for low-to-moderate doses of fentanyl (5–15  $\mu\text{g}/\text{kg}$ ) is estimated using serum levels in the region of this limit. Accordingly, limitations of the assay, whether radioimmunoassay or gas liquid chromatography, must be considered in interpreting studies that profile fentanyl pharmacokinetics.

Fentanyl has both high lipid solubility and a pattern of

rapid and extensive redistribution, making it an ideal agent to evaluate drug delivery systems and routes of administration other than the traditional parenteral routes. Consequently, it has been administered *via* intramuscular, intravenous (bolus injection, infusion, patient-controlled analgesia [PCA]), neuraxial (epidural, intrathecal), transdermal, transmucosal (oral or intranasal), and inhalational routes.

## Systemic Administration: Intravenous

### Pharmacokinetics

After an intravenous bolus, fentanyl distributes rapidly from plasma to highly vascular tissues (heart, lung, and brain). More than 80% of the injected dose leaves plasma in less than 5 min,<sup>26</sup> and 98.6% leaves by 1 h.<sup>27</sup> Elimination from the vascular tissue also is rapid as fentanyl redistributes to other sites, such as muscle and fat.<sup>28</sup> In rats, fentanyl  $C_p$  peaks in muscle 5 min after a bolus dose, and in fat at approximately 30 min (fig. 1). Removal from muscle and fat is slower than uptake, because both tissues act as storage sites; in muscle this is because of its mass, and in fat because of the high lipid solubility of fentanyl.<sup>29</sup> After initial equilibration with adipose tissue, fentanyl  $C_p$  decreases, and then fat slowly releases the fentanyl back into the plasma. This slow release results in a lengthy elimination half-time of 3.1 to 7.9 h (table 1). Thus, fentanyl's short duration of action after a single dose results from redistribution rather than elimination. After large or multiple smaller doses, fentanyl accumulates as a result of its long half-time, and redistribution is less effective in removing fentanyl from its site of action in the brain.<sup>9,30</sup>

Fentanyl is metabolized almost exclusively in the liver to norfentanyl, hydroxy-propionyl-fentanyl, and hydroxypropionyl-norfentanyl.<sup>31</sup> The pharmacologic activity of fentanyl metabolites is unknown but is believed to be minimal.<sup>31</sup> Less than 10% of fentanyl is excreted unchanged by the kidney.<sup>27</sup> The total body clearance of fentanyl is high, between 8 and 21  $\text{ml} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ , and approaches that of liver blood flow, reflecting the high hepatic extraction ratio. The high lipid solubility of fentanyl contributes to a large volume of distribution (3.2–5.6 l/kg).

### Pharmacodynamics

Several studies correlate fentanyl  $C_p$  with analgesia (the desired effect) and respiratory depression (the most dangerous side effect). However, the intensity of fenta-




Fig. 1. Concentrations of unchanged fentanyl in muscle, fat, and plasma after an intravenous injection of 50  $\mu\text{g}/\text{kg}$  in six rats. Each data point represents the mean  $\pm$  SEM. Reprinted with permission.<sup>28</sup>

nyl's effect correlates with the drug concentration at the site of action (effect site) and not necessarily the plasma concentration. For opioids, the effect site or biophase is the opioid receptor in the brain and spinal cord. Additional time is needed for fentanyl to cross the blood-brain barrier to reach the effect site. The temporal lag between plasma concentration and the effect on the biophase is called hysteresis. A first-order rate constant ( $k_{eo}$ ) characterizes the temporal aspects of equilibration between the effect-compartment concentration and the serum concentration. Thus, the half-time for equilibration  $t_{1/2k_{eo}}$  ( $0.693/k_{eo}$ ) quantifies the magnitude of the hysteresis (table 1). Using electroencephalography to measure opioid effect, one group of investigators found a 3- to 5-min lag between increasing fentanyl  $C_p$  and electroencephalography slowing during a 5-min fentanyl infusion.<sup>32</sup> After the infusion was discontinued, resolution of electroencephalography changes lagged behind decreasing fentanyl  $C_p$  by 10 to 20 min (fig. 2).

Different modes of administration have different de-

grees of hysteresis. With a rapid change in plasma concentration (e.g., after an intravenous bolus), the temporal lag will be greatest; with a slow change in concentration (e.g., with a steady continuous infusion), the lag will be smallest. Consequently, pharmacodynamic data obtained *via* different modes must be compared with caution.

#### Plasma Fentanyl Concentration and Analgesia.

Most studies correlating fentanyl  $C_p$  with its analgesic and side effects have estimated plasma fentanyl from gradually changing concentrations in selected groups of patients. Data from studies limited primarily to patients receiving intravenous fentanyl for postoperative analgesia indicate a mean analgesic  $C_p$  ranging from 0.6–3 ng/ml.<sup>14,15,17,18,33–38</sup> Infusion of fentanyl to achieve a steady state  $C_p$  is reported in one study<sup>14</sup> to produce "slight but significant analgesia" at a mean concentration of 0.6 ng/ml and "significantly greater analgesia" at a  $C_p$  of 1.7 ng/ml, and, in another,<sup>35</sup> an analgesic range of 1–3 ng/ml. With PCA, the mean minimum effective analgesic concentration (MEC—fentanyl  $C_p$  immediately before the patient administers the next bolus dose<sup>37</sup>) has been reported as 1.35 ng/ml,<sup>15</sup> 1.54 ng/ml,<sup>36</sup> and 0.63 ng/ml.<sup>37</sup> Thus, mean MEC values range from 0.6–1.54 ng/ml, whereas values for individual patients range from 0.2–8.0 ng/ml with a log-normal distribution.<sup>15</sup>

Studies correlating fentanyl  $C_p$  with analgesic effect *via* visual analog pain scale ([VAS] 0 = no pain, 10 = maximum pain) scores report that the mean fentanyl  $C_p$  of 0.3 to 0.7 ng/ml and 0.5 to 1.2 ng/ml during PCA correlate with VAS scores at rest of 3 or 4<sup>19</sup> and 2 to 4,<sup>16</sup> respectively. Scores of 1 to 3 are associated with a  $C_p$  of 1 or 2 ng/ml in different postoperative patient populations (thoracotomy,<sup>17,18</sup> cesarean section,<sup>38</sup> knee sur-




Fig. 2. The time course of the electroencephalogram spectral edge and serum fentanyl concentrations. The spectral edge axis is inverted. The electroencephalogram spectral edge changes lag behind changes in serum concentration. Fentanyl infusion rate = 150  $\mu\text{g}/\text{kg}$  (solid bar). Reprinted with permission.<sup>32</sup>

## FENTANYL AND ACUTE PAIN MANAGEMENT

gery<sup>39</sup>) treated by a bolus dose plus infusion of fentanyl. However, measurements of the  $C_p$  associated with effective analgesia often are obtained while patients are at rest; at a similar  $C_p$ , VAS scores markedly increase with movement or coughing.<sup>39</sup>

The observed variability in the analgesic  $C_p$  reported for fentanyl in large part is caused by differences in study design and in individual pharmacodynamic responses. Analgesic requirements of individual patients and different surgical populations vary over a sixfold range for fentanyl and other opioids.<sup>15,37,40</sup> With respect to study design, the residual presence of anesthetic drugs and possible coadministration of central nervous system depressants affect the relation between doses or the  $C_p$  of fentanyl and the intensity of analgesia and side effects. The degree of drug interaction also varies by study design. The types of surgical procedure also alter the degree of postoperative pain, and thereby the analgesic requirement: With a similar study design, we would expect a higher analgesic requirement in patients undergoing thoracotomy than hysterectomy. Different measurements of analgesic effect are used, including descriptive terms,<sup>14</sup> MEC,<sup>37</sup>  $C_p$  associated with 50% reduction in pain intensity,<sup>33</sup> and VAS score.<sup>17-19,38</sup> The timing of blood sampling also differs: Some investigators sample at predetermined intervals, correlating these results with analgesic effect,<sup>38</sup> whereas others measuring MEC sample just before the patient administers the next bolus.<sup>15,36,37</sup>

Intravenously administered fentanyl produces effective analgesia in patients after operation at  $C_p$  values ranging from 0.6–3.0 ng/ml. Pain control at rest is satisfactory within this range, but the analgesic effect diminishes with movement or coughing,<sup>39</sup> suggesting that a higher  $C_p$  may be required if analgesia is intended to promote either of these responses.

**Plasma Fentanyl Concentration and Respiratory Depression.** Studies investigating the connection between fentanyl  $C_p$  and ventilatory effect show a concentration-effect relation.<sup>33,41</sup> With intravenous bolus elimination, a  $C_p$  of 3 or 4 ng/ml produces a 50% decrease in the slope of minute ventilation ( $V_E$ ) versus end-tidal carbon dioxide concentration.<sup>20,21,42</sup> However, these measured plasma concentrations may not reflect effect-site concentrations of fentanyl, as a result of the hysteresis between these values with bolus administra-

tion. Other studies using prolonged infusions or loading dose/maintenance infusions thus provide a better reflection of the steady state concentration-effect relations for fentanyl,<sup>33</sup> and these report clinically significant respiratory depression in both patients undergoing surgery<sup>1,34,43</sup> and volunteers<sup>33</sup> at a steady state  $C_p$  of 2 ng/ml or more. For this review, we define clinically significant respiratory depression as a requirement for intervention with naloxone administration, resuscitation, or cessation of fentanyl treatment.

Fentanyl-induced respiratory depression has been measured primarily by assessing the ventilatory response to carbon dioxide using the carbon dioxide rebreathing technique. Although an altered carbon dioxide response may indicate depression of central respiratory control, this approach may be impractical in patients after operation because it relies on patient cooperation and is significantly affected by alertness and arousal, conditions that are likely to vary among patients.<sup>44</sup> Continuous measurement of ventilation therefore is preferable, particularly to detect the occurrence of apnea, hypopnea, slow respiratory rate, or hypoxemia, the development of which will not be detected by discrete measurement.<sup>44</sup>

Respiratory inductive plethysmography and pulse oximetry have been used to monitor the occurrence of episodes of apnea (tidal volume < 100 ml for > 15 s in adults) and slow respiratory rate (< 8 breaths/min for > 5 min).<sup>45-47</sup> Using these methods, Sandler *et al.*<sup>18</sup> reported a baseline occurrence of three apnea episodes per hour before operation in patients undergoing thoracotomy. In the postoperative period, a steady state  $C_p$  of 1 or 2 ng/ml was associated with VAS pain scores of 2 at rest, a moderate increase in apneic episodes and slow respiratory rates, and the partial pressure of carbon dioxide arterial blood levels of 47–49 mmHg. This degree of respiratory depression did not require intervention.

There is a direct concentration-effect relation between the  $C_p$  fentanyl and respiratory depression. Plasma concentrations greater than 2 ng/ml are associated with clinically significant respiratory depression. However, the degree of respiratory depression is affected by various factors, including the types of surgical population, level of noxious stimulation, age, and individual pharmacodynamic responses. Thus, a threshold greater than 2 ng/ml should serve primarily as a guideline for clinicians.

**Therapeutic Window.** The therapeutic window for fentanyl analgesia is the range between the minimally effective analgesic concentration and that associated with respiratory depression.<sup>48</sup> Studies in volunteers al-

‡ Howell ST, Minto CF, Schlugman D, Glass PSA: Respiratory pharmacodynamics of bolus fentanyl in healthy volunteers (Abstract). ANESTHESIOLOGY 1996; 85:A339.

**Table 2. Continuous Fixed or Variable iv Fentanyl Infusion Studies (Non-PCA)**

Study	Dosage	Analgesia	Mean Plasma Concentration (ng/ml)
Nimmo <sup>14</sup>	0.5 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	50% patients good	0.56–0.61
	1.5 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	90% patients good	1.62–1.79
Duthie <sup>35</sup>	1.48 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	No pain 85–93%	1.4–2.2
Duthie <sup>49</sup>	1.56 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	N/A	0.5–2.3
Holley <sup>50</sup>	25 $\mu\text{g}/\text{h}$	VAS 0–3	0.51–0.53
	50 $\mu\text{g}/\text{h}$		0.87–0.94
	100 $\mu\text{g}/\text{h}$		1.37–1.42
	125 $\mu\text{g}/\text{h}$		1.90–1.97
Ellis <sup>38</sup>	0.75–2.25 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ (mean = 1.88)	VAS 1.4–2.0	1.16–1.19
Loper <sup>39</sup>	100 $\mu\text{g}/\text{h}$	VAS 1–3 (rest)	1.75
		VAS 4–7 (movement)	
Salomaki <sup>17</sup>	1.67–2.41 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	VAS 1–2	1.38–1.54
Sandler <sup>18</sup>	1.4–1.6 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	VAS 1–3	1.5–1.7
Guinard <sup>52</sup>	1.25–2.0 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ (mean=1.2)	VAS <3 (rest)	N/A
		VAS 4–7 (cough)	
Bernard <sup>51</sup>	1.25 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	VAS 1–3	1.3–1.5 (1.10)

VAS = 0–10 cm visual analog pain scale (0 = no pain, 10 = maximum pain); N/A = not applicable.

low the complex relations among analgesic effect, side effects, and fentanyl  $C_p$  to be evaluated under highly controlled conditions. In volunteers,<sup>33</sup> as in patients, the magnitude of analgesia and respiratory depression has a direct relation to the fentanyl  $C_p$ . The lowest concentration producing slight, but measurable analgesia, without having significant ventilatory effect in volunteers<sup>33</sup> and patients<sup>14</sup> is 0.6 ng/ml. At plasma concentrations at which pain intensity decreases by 50% ( $C_p$  associated with 50% reduction in pain intensity = 1.4 ng/ml), fentanyl decreases the slope of the  $V_E$  versus end-tidal carbon dioxide concentration curve in volunteers by 33% and  $V_E$  by 12%. At a  $C_p$  of 3 ng/ml, fentanyl produces profound analgesia and decreases this slope by 54% and  $V_E$  by 23%. Thus, the therapeutic margin in volunteers correlates reasonably well with that just described for patients after operation.

There is a direct concentration-effect relation between fentanyl  $C_p$  and analgesia and respiratory depression. In volunteers and patients, the range of fentanyl  $C_p$  providing analgesia without clinically significant respiratory depression is 0.6–2 ng/ml. Factors including type of surgical procedure, surgical population (e.g., elderly patients), interaction with other central depressive drugs, and individual pharmacodynamic and pharmacokinetic differences can markedly influence this window and should be considered when the suggested therapeutic range is applied.

**Modes of Administration.** Fentanyl can be administered intravenously for postoperative analgesia using a loading (bolus) dose with a continuous fixed or variable

infusion, a fixed background infusion with PCA, or PCA alone.

**Continuous Background Intravenous Fentanyl Infusion.** Continuous intravenous infusions of fentanyl have been used to provide postoperative analgesia after abdominal,<sup>14,35,49</sup> peripheral orthopedic,<sup>35,39,50</sup> and major spinal surgery<sup>51</sup>; thoracotomy<sup>17,18,50,52</sup>; and cesarean section delivery<sup>38</sup> (table 2).

**Dose Requirements.** An intravenous bolus of fentanyl (1 or 2  $\mu\text{g}/\text{kg}$ ) usually is administered before the start of infusion. If variable, the infusion rate is 1 or 2  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$  (table 2) and may be adjusted upward or downward as required by fluctuations in analgesic requirements or increasing side effects. Before the infusion rate is increased, small bolus doses of fentanyl are administered to increase the  $C_p$  rapidly.<sup>17,18,38,39</sup> If the infusion rate is fixed, a supplementary analgesic technique, either bolus or PCA doses of nonsteroidal antiinflammatory drugs, fentanyl, or morphine (table 2), is used to meet the therapeutic demand.<sup>35,50,51</sup>

**Analgesic Efficacy.** Infusion of fentanyl, especially at rates of 1.5–2.5  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ , can provide good-to-excellent postoperative analgesia (table 2). At rest, the quality of analgesia remains stable; with movement (ambulation, coughing), it decreases significantly, even with higher infusion rates.<sup>39,52</sup> The fentanyl  $C_p$  relates directly to the infusion rate,<sup>50</sup> with good analgesia at rest associated with concentrations ranging from 0.5–2.3 ng/ml.

**Side Effects.** Nonrespiratory side effects can occur. The incidence of nausea and vomiting after fentanyl infusion varies from 20–60%. Pruritus occurs in 0–30%

## FENTANYL AND ACUTE PAIN MANAGEMENT

of patients, and urinary retention occurs in 40–45%. The latter values may over- or underestimate the actual incidence of urinary retention, because many studies use postoperative indwelling urinary catheters that preclude measurement of urinary retention.

Respiratory depression is common after fentanyl infusion, but most events are not significant. Only three studies<sup>17,50,51</sup> have reported clinically significant respiratory depression. Comparing these three with other studies (table 2) reveals similar infusion doses, types of surgery, and other factors (e.g., systemic morphine supplementation), making it unclear why the incidence of respiratory depression differed significantly. The methods of detection and measurement of respiratory depression include intermittent or continuous measurement of respiratory rate, pulse oximetry, respiratory inductive plethysmography, and intermittent arterial blood sampling.

Continuous intravenous fentanyl infusion provides good-to-excellent analgesia (particularly at rest) at doses of 1 or 2  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ . Naturally occurring variations in postoperative analgesic requirements can be managed by adjusting the fentanyl infusion rate upward or downward, as needed, assuming a variable infusion technique, or by parenteral administration of bolus doses of opioid or nonsteroidal antiinflammatory drugs to supplement a fixed infusion.

**Continuous Background Intravenous Infusion with Patient-Controlled Analgesia.** A background low-dose intravenous infusion of fentanyl may be combined with PCA to provide satisfactory analgesia with potentially fewer adverse effects.<sup>15,36,53–58</sup>

**Dose Requirements.** Patient-controlled analgesia bolus doses typically range from 7–50  $\mu\text{g}$ . Background infusion rates may be fixed, ranging from 4–60  $\mu\text{g}/\text{h}$ , or be variable, adjusted up and down according to clinical criteria<sup>54,55</sup> (table 3). Generally, the larger the background infusion rate, the smaller the PCA bolus dose. Lockout intervals (minimum time period between doses) range from “on demand” (i.e., no lockout) to 15 min, the most common interval being 1–5 min (table 3).

No study directly compares the use of intravenous fentanyl infusion with and without fentanyl PCA. However, examination of the data in tables 2 and 3 reveals a smaller dose requirement for continuous infusion plus PCA than for infusion alone, despite variability in infusion rate, PCA dose, and lockout interval. The type of surgery also influences the dose requirement; that is, thoracotomy generates higher requirements than does orthopedic or lower abdominal surgery.<sup>59</sup>

Table 3. Patient-controlled Analgesia + Background iv Fentanyl Infusion Studies

Study	Dosage				Mean Hourly Dose	Analgesia	Plasma Concentration (ng/ml)
	Demand Bolus ( $\mu\text{g}$ )	Basal Infusion ( $\mu\text{g}/\text{h}$ )	Lockout Interval (min)	Max ( $\mu\text{g}/\text{h}$ )			
White <sup>53</sup>	10–15	30	2	150	44	VAS 2.0 (0.4–4.4)	N/A
Kay <sup>56</sup>	12.5	15	1–5	250	53	Pain relief rating good	N/A
Rosenberg <sup>54</sup>	7–13.5	32–59	None	225–315	58	VAS 2–4	N/A
Hackl <sup>56</sup>	9	54	1	270	88	VAS 2–3	1.54 $\pm$ 0.35 (MEC) Range 0.4–3.4
Gourlay <sup>37</sup>	20	20	5	180	56	Not measured	0.63 $\pm$ 0.25 (MEC) Range 0.2–1.2
Lehmann <sup>15</sup>	34.5	4	1	250	40–70	1.07 (pain scale 1–6)	1.35 $\pm$ 0.86 (MEC) Range 0.2–8.0
Welchew and Breen <sup>57</sup>	20	20	2	N/A	98	VAS 1–4	N/A
Lehmann <sup>58</sup>	34	4	1	250	40–60	0.3–0.6 (pain scale 1–3)	N/A
Grant <sup>55</sup>	50	0.75–2 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	15	N/A	128	VAS 1.5–5 (rest) VAS 5–7 (cough)	N/A

MEC = minimum effective analgesic concentration; Max = maximum dose allowable per hour; VAS = verbal or visual analogue score for pain (0 = no pain; 10 = worst imaginable pain); N/A = not available.

Table 4. Patient-controlled analgesia (PCA) Fentanyl Studies without Background Infusion (PCA Only Mode)

Study*	Dosage			Mean Hourly Dose ( $\mu\text{g/h}$ )	Analgesia VAS Score	Plasma Concentration (ng/ml)
	Bolus ( $\mu\text{g}$ )	Lockout Interval (min)	Max ( $\mu\text{g/h}$ )			
Welchew <sup>64</sup>	N/A	None	600	83	2-4	N/A
Suttman <sup>66</sup>	50	5	150	46.8		N/A
Rowbotham <sup>16</sup>	20	6	200	Not measured	2-4	1.4-1.2
Lehmann <sup>63</sup>	34	5	400	68	2-3	N/A
				( $0.93 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ )		
Glass <sup>19</sup>	20	6	200	48	2-4	0.3-0.4
				(0-6 h postop)	(0-6 postop)	(0-6 postop)
Laitinen <sup>65</sup>	50	5	500	68	1-3	N/A
Cooper <sup>63</sup>	20	10	120	40	2-5 (rest)	N/A
					3-6.5 (cough)	
Howell <sup>60</sup>	25	10	150	78	1-4	N/A
Ginsberg <sup>61</sup>	13.8-14.4	5-8	—	N/A	3-5	N/A

N/A = not available; B = demand bolus; LO = lockout interval; Max = maximum allowable hourly dose; VAS = visual analogue scale (0 = no pain; 10 = worst imaginable pain)

\* Studies with VAS measurement only.

**Analgesic Efficacy.** The technique of background infusion plus PCA produces excellent postoperative pain relief for abdominal,<sup>15,37,54,56,57</sup> orthopedic<sup>15</sup> and peripheral vascular surgery<sup>54</sup> and for thoracotomy.<sup>55,58</sup> Consistent with the primary fentanyl infusion studies, pain has been measured in patients at rest<sup>15,58</sup> and increased markedly with movement.<sup>55</sup>

Studies of the concentration-effect relation with this technique have shown a MEC value for fentanyl for abdominal and orthopedic surgery that varies from 0.63-1.54 ng/ml.<sup>15,36,37</sup>

**Side Effects.** Nonrespiratory side effects can occur, but data regarding the incidence of adverse effects with this technique are limited. Nausea and vomiting are estimated to occur in approximately 30-40% of patients. Only two studies have investigated the incidence of pruritus, reporting a range of 7-13%,<sup>55,58</sup> and none have studied the occurrence of urinary retention.

Of nine studies, only five report the incidence of respiratory depression, and none show evidence of clinically significant respiratory depression requiring treatment.

Compared with continuous infusion alone, the use of a background fentanyl infusion with PCA fentanyl provides excellent postoperative analgesia, with a lower total dose consumption. The incidence of side effects with the two techniques is difficult to compare because of the limited data published for background infusion.

**Patient-Controlled Analgesia.** Fentanyl is rarely used alone for PCA, most likely because of the wide-

spread belief in its brief duration of action. The opioids most commonly administered are morphine and meperidine. Consequently, only a few studies have compared the efficacy and safety of PCA fentanyl with those of other opioids,<sup>60-62</sup> but other investigators have used PCA fentanyl only as a control in clinical trials comparing it with other analgesic techniques<sup>16,19,63-67</sup> (table 4).

**Dose Requirements.** Consistent with other opioids used for PCA,<sup>60,62</sup> fentanyl dose requirements vary widely.<sup>36,68</sup> Bolus doses range from 20-50  $\mu\text{g}$  with lockout intervals from "on demand" to 10 min. Theoretically, the lockout interval should relate to the time from drug administered to peak effect so that patients can experience the full effect of a dose before receiving a subsequent dose.<sup>61</sup> Because of fentanyl's short latency to peak effect,<sup>68</sup> a lockout interval of 5 or 6 min is reasonable.

Maximum hourly PCA dosage varies from 120-600  $\mu\text{g/h}$ , and mean hourly requirements vary from 48-83  $\mu\text{g/h}$  (table 4), less than those for the continuous infusion technique (table 2). Despite fentanyl's brief duration of action, patients typically require only one to three doses/h and rarely administer more than two bolus doses/h.<sup>63,69,70</sup> At bolus doses of 20-50  $\mu\text{g}$ , fentanyl therefore might be suitable for PCA use.

**Analgesic Efficacy.** Good analgesia can be achieved with PCA fentanyl alone, with efficacy comparable to that of morphine and meperidine.<sup>61,62</sup> Only two studies,<sup>60,67</sup> both using small bolus doses (20-25  $\mu\text{g}$ ) and a long lockout interval (10 min), report inadequate analgesia.

No study has directly compared the influence of a background infusion on the efficacy of intravenous fentanyl delivered by PCA. Comparing individual studies in tables 3 and 4 suggests that PCA fentanyl alone produces similarly effective analgesia with similar dose requirements as PCA with a background infusion. Most studies of other opioids fail to show any benefit to adding a background infusion to PCA.<sup>71-74</sup> Furthermore, the use of such an infusion increases opioid requirements<sup>71-73,75</sup> and is associated with an increased risk for severe respiratory depression.<sup>76-78</sup> Therefore, it may be prudent to avoid using background infusions with PCA fentanyl.

Depending on the dose and lockout interval set for the PCA device, relatively effective analgesic fentanyl  $C_p$  can be achieved and maintained with PCA fentanyl alone. In an unblinded trial of 11 patients undergoing upper abdominal surgery,<sup>16</sup> a bolus dose of 20  $\mu$ g with a lockout interval of 6 min resulted in a mean fentanyl  $C_p$  of  $1.4 \pm 0.7$  ng/ml (mean  $\pm$  SD) 12 h after operation, which decreased to  $0.5 \pm 0.2$  ng/ml at 48 h. Mean VAS pain scores at rest at 12 and 48 h were acceptable at 4 and 3, respectively. Comparing PCA fentanyl administered through the epidural route with PCA intravenous fentanyl in patients undergoing lower limb orthopedic or abdominal surgery, Glass *et al.*<sup>19</sup> conducted a randomized, double-blind, crossover trial using the same 20- $\mu$ g bolus dose and 6-min lockout interval. Fentanyl  $C_p$  for the first 6 h in the intravenous PCA group ranged from 0.2-0.4 ng/ml, resulting in mean VAS scores for this period of 2 to 4 at rest (*i.e.*, moderate-to-good analgesia).

**Side Effects.** Only a few studies have reported the incidence of nonrespiratory side effects with PCA fentanyl alone. Nausea and vomiting occur in 20-60% of patients and pruritus occurs in 0-40%.

There are no reports of clinically significant respiratory depression with PCA fentanyl alone. However, all these studies thus far monitored respiratory depression solely by respiratory rate, which correlates poorly with ventilatory insufficiency.<sup>44</sup>

Patient-controlled analgesia fentanyl provides analgesia comparable to that of other intravenous modes of administration. Despite fentanyl's short duration of action, most patients require only one to three bolus doses/h. The addition of a background infusion offers no benefit to the quality of analgesia and potentially increases the risk of respiratory depression. Compared with continuous infusion, average dose consumption is less with PCA alone.

## Systemic Administration: Transdermal

Transdermal delivery of fentanyl has been investigated extensively. This modality is simple, noninvasive, and allows continuous release of fentanyl into the systemic circulation. The major barrier to the entry of transdermally administered drug into the systemic circulation is the stratum corneum of the epidermis.<sup>79</sup> This layer of skin has a "brick-and-mortar" arrangement of keratin-rich cells embedded in a lipid matrix arranged in broad sheets forming multiple layers. However, fentanyl's lipid-soluble properties allow it to diffuse through the stratum corneum *via* the intercellular lipid medium.<sup>80</sup>

### Passive (Conventional) Transdermal Fentanyl Administration

Permeability of the stratum corneum may be affected by various factors, including body site, skin temperature, skin damage, ethnic group, or age. To ensure a predictable rate of drug transfer, the transdermal delivery system minimizes the influence of skin in transfer by incorporating a rate-controlling membrane more impermeable than skin.

The Therapeutic Transdermal System (TTS; ALZA Corp., Palo Alto, CA) uses the membrane permeation model.<sup>81</sup> This transdermal fentanyl patch is available in four sizes and provides sustained release of fentanyl at rates of approximately 25, 50, 75, and 100  $\mu$ g/h for periods of 48-72 h. The patch is attached to the skin by a contact adhesive, adjacent to which is a microporous membrane that controls the rate at which fentanyl is transferred from the drug reservoir to the skin (fig. 3). The reservoir is a shallow compartment with a gel matrix containing as much as 10 mg fentanyl, intended to provide a sufficiently high concentration gradient for diffusion across the skin. To prevent escape of the fentanyl matrix into the environment, the reservoir has a backing.

An important feature of the TTS design is that it takes advantage of the substantial capacity of the skin layers to act as a secondary reservoir. The presence of skin depot has several implications: It dampens the fluctuations of fentanyl effect, needs to be reasonably filled before significant vascular absorption occurs, and contributes to a prolonged residual fentanyl  $C_p$  after patch removal.<sup>45</sup> The amount of fentanyl remaining within the system and skin depot after removal of the patch is substantial: At the end of a 24-h period with a TTS fentanyl patch releasing drug at the rate of 100  $\mu$ g/h,  $1.07 \pm 0.43$  mg fentanyl (approximately 30% of the total delivered dose from the patch) remains in the skin depot.<sup>24</sup>






Fig. 3. The TTS-100 transdermal fentanyl delivery system. Reprinted with permission.<sup>24</sup>

**Pharmacokinetics.** Pharmacokinetic studies have examined absorption, plateau systemic concentrations, time to peak concentration, and apparent elimination half-life after removal of the TTS fentanyl patch.<sup>24,45,49,50,82-89</sup>

There are two distinct phases of fentanyl absorption after a 24-h application of the TTS patch: An initial phase with rapid skin absorption of the drug from the contact adhesive because of the large concentration gradient between the patch and the skin reservoir, and a plateau phase with sustained release of drug from the reservoir.<sup>24</sup> Because of the presence of the skin reservoir,  $C_p$  peaks an average of 24 h (range, 14-28 h) after the patch is applied. During a steady state infusion, the plateau systemic concentration is proportional to the "infusion rate" of the TTS fentanyl patch ( $C_p = \text{infusion rate}/\text{clearance}$ ). The plateau systemic concentration values for the TTS patch doses of 50, 75, and 100  $\mu\text{g}/\text{h}$  are approximately 1, 1.5, and 2 ng/ml, respectively, well within the analgesic range for fentanyl. However, there is large interpatient variability in peak systemic concentration: Peak fentanyl  $C_p$  within 24 h of application of the 75- $\mu\text{g}/\text{h}$  TTS fentanyl patch ranges from 1-5.5 ng/ml.<sup>24,82,83,90</sup> The actual infusion rate for the 75- $\mu\text{g}/\text{h}$  patch, estimated from the formula (initial fentanyl amount - residual fentanyl amount)/duration of system application, ranges from 60-130  $\mu\text{g}/\text{h}$ .<sup>90</sup>

When a TTS fentanyl patch is kept *in situ* for 72 h, fentanyl  $C_p$  tends to decrease after 48 h.<sup>45,88,89</sup> After the patch is removed, fentanyl  $C_p$  decreases slowly because

of continued absorption from the fentanyl skin depot. The apparent terminal half-time ranges from 16-25 h. Mean bioavailability is  $92 \pm 33\%$ , which is determined by calculating the total systemic absorption of fentanyl and measuring the total fentanyl administration (loss from the patch).<sup>24</sup>

**Dose Requirements.** Dose requirements using TTS fentanyl are difficult to match to individual patients or types of surgery, because the TTS fentanyl device is a constant-rate infusion system that requires a long time to reach a plateau  $C_p$ . In general, the patch size is selected empirically to match the magnitude of postoperative pain associated with the surgical procedure.<sup>45</sup> Severe postoperative pain after major abdominal surgery usually is managed with the TTS patch releasing a 100- $\mu\text{g}/\text{h}$  dose, whereas mild to moderate pain after lower abdominal surgery warrants the patch releasing the 50- $\mu\text{g}/\text{h}$  dose. Because the release of fentanyl from the TTS patch is similar to that from a fixed intravenous infusion, systemic opioids (morphine, fentanyl, piritramide) are used to supplement individual analgesic requirements as needed. Because of the slow attainment of an analgesic  $C_p$ , patches usually are applied before operation at varying time intervals, including immediately before surgery<sup>84</sup> and at 0.5,<sup>85</sup> 1,<sup>91</sup> 2,<sup>45,49,50,79,83,86,92</sup> and 8 h<sup>58</sup> after operation. The effect of a single patch application lasts 24-72 h.<sup>45,87,90-92</sup>

**Analgesic Efficacy.** The TTS fentanyl system provides a steady release of fentanyl to the systemic circulation without the flexibility of dose adjustment. This may result in poor matching to the rapidly changing intensity of postoperative pain. Thus, parenteral opioids are necessary to supplement analgesia and have been administered in all studies evaluating the transdermal patch to treat acute postoperative pain. With supplementation, TTS fentanyl produces significantly better postoperative analgesia than supplemental opioid alone, independent of the route of administration,<sup>45,79,84-86,93</sup> and TTS fentanyl significantly reduces the supplemental dose requirement.<sup>45,58,79,84-86,91</sup>

**Side Effects.** The incidence of nausea and vomiting with TTS ranges from 10-90%. In most studies, it is 50-60%. These values are comparable to those associated with intravenous modalities and the control groups with "rescue" opioid (morphine and meperidine) bolus administration.<sup>45,91,93</sup> Pruritus occurs in 4-39% of patients but typically does not require treatment. Urinary retention has been measured in only a few studies at a rate of 3-27%. Skin reaction (erythema) occurs in 20-60% of patients, but it is rarely severe enough to warrant

## FENTANYL AND ACUTE PAIN MANAGEMENT

Table 5. Transdermal Therapeutic System (TTS) Fentanyl: Respiratory Side Effect

Study	Delivery Rate ( $\mu\text{g}/\text{h}$ )	Respiratory Depression Parameter/Measurement	CSRD	
			Active (%)	Placebo (%)
Von Bormann <sup>85</sup>	75	SRR, $\text{PA}_{\text{CO}_2}$ , $\text{Pa}_{\text{O}_2}$	1/20 (5)	0/20 (0)
Duthie <sup>49</sup>	100	SRR	2/9 (22)	0 (0)
Holley <sup>50</sup>	100	SRR	0/8 (0)	0/6 (0)
Plezia <sup>83</sup>	75	AP, SRR	1/7 (14)	—
Gourley <sup>87</sup>	50–125	SRR	3/13 (23)	—
Caplan <sup>84</sup>	75	SRR	0/22 (0)	0/20 (0)
Latasch <sup>82</sup>	75	SRR, $\text{Pa}_{\text{CO}_2}$	0/28 (0)	0/29 (0)
Rowbotham <sup>86</sup>	100	SRR	0/22 (0)	0/8 (0)
Gourlay <sup>90</sup>	25–75	SRR	0/20 (0)	0/20 (0)
Lehmann <sup>63</sup>	75	SRR	0/25 (0)	0/25 (0)
Sevarino <sup>91</sup>	25, 50	SRR, $\text{Sp}_{\text{O}_2}$	1/64 (2)	0/31 (0)
Sandler <sup>45</sup>	50, 75	AP, SRR, $\text{Sp}_{\text{O}_2}$	37/80 (46)	7/40 (18)
Broome <sup>89</sup>	20, 50, 75	SRR, $\text{Sp}_{\text{O}_2}$	1/61 (2)	0/20 (0)
Van Bastelaere <sup>88</sup>	75	SRR, $\text{Sp}_{\text{O}_2}$	1/20 (5)	0/20 (0)

Active = TTS group; Placebo = placebo TTS group; SRR = slow respiratory rate ( $<10/\text{min}$ ); AP = apneic episodes;  $\text{Sp}_{\text{O}_2}$  = hemoglobin desaturation  $\leq 90$ ; TTS = transdermal therapeutic system fentanyl with rate-controlling membrane (see text); CSRD = clinically significant respiratory depression: defined as respiratory depression requiring intervention, *i.e.*, naloxone administration, resuscitation, or cessation of fentanyl treatment.

early removal of the TTS fentanyl patch and seldom persists longer than 24 h after the patch is removed.

Table 5 shows the incidence, characteristics, and severity of respiratory depression reported by TTS fentanyl studies.

Premarketing evaluation of the safety and effectiveness of the TTS fentanyl system (Duragesic; Janssen Pharmaceutica, NJ) to treat postoperative pain found a high incidence of hypoventilation, resulting, in some cases, in death.<sup>94</sup> A review<sup>95</sup> of the literature on the use of TTS fentanyl patches reveals a high incidence of clinically significant respiratory depression, confirming risk (table 5). Without further improvement in the mode of delivery or restriction of its use in closely monitored settings, the transdermal fentanyl patch delivery system cannot be recommended to treat acute pain of any origin. The Food and Drug Administration has made specific recommendations that the TTS fentanyl system should not be used to treat acute pain.

Slow onset time, inability to adjust dose during the period of application, persistent  $C_p$ , and a high incidence of respiratory depression make the transdermal fentanyl patch delivery system undesirable to treat acute pain of any origin.

#### Active (Iontophoretic) Transdermal Fentanyl System

To overcome the resistance to drug absorption of the stratum corneum layer of the epidermis, new methods of enhancing transdermal drug penetration and absorption are being investigated.

Iontophoresis is one method to enhance transdermal drug delivery. The system consists of a skin delivery electrode, a skin current returning electrode, and an electric power source. By applying an external electric field, electrically charged components of drug are propelled through the skin.<sup>81</sup> This approach for noninvasive administration has been used to deliver corticosteroids to treat joint pain,<sup>96,97</sup> local anesthetics (lidocaine) for analgesia for minor surgical procedures,<sup>98</sup> and clinically significant doses of morphine.<sup>99</sup>

Iontophoretic administration of fentanyl has been studied in volunteers.<sup>100</sup> Fentanyl (3 mg/ml) was applied for 2 h at 1 and 2 mA of current, respectively, on two occasions 2 weeks apart. Mean times to initial detection of fentanyl in the systemic circulation for the 1-mA and 2-mA applications were 33 min (range, 10–50 min) and 19 min (range, 15–20 min), respectively. Mean times to 0.5  $\mu\text{g}/\text{ml}$   $C_p$  were 92 and 36 min, and the mean times to maximum concentrations were 122 and 119 min. Maximum  $C_p$  was  $0.76 \pm 0.23$  ng/ml (mean  $\pm$  SD) with the 1-mA application and was approximately double that with the 2-mA application (fig. 4). The mean terminal half-life was similar for both the 1-mA and the 2-mA application,  $354 \pm 100$  and  $413 \pm 106$  min, respectively. The results indicate a significant relation between charge and the administered fentanyl dose. Fentanyl  $C_p$  increased throughout the 2-h delivery time.

Adverse events, including pruritus, transient hemoglobin desaturation, and hypoxemia occurred in several volunteers. Erythema was observed at the site of the




Fig. 4. Plasma fentanyl concentrations (mean  $\pm$  SE) versus time (0–660 min) after a 120-min iontophoretic delivery at 0 mA, 1 mA, and 2 mA current. Reprinted with permission.<sup>100</sup>

dispersive pad but resolved without treatment within 24 h. No studies have described iontophoretic fentanyl use for postoperative analgesia.

Iontophoresis can be used to deliver clinically significant doses of fentanyl. A charge-dose relation has been documented for fentanyl administration by this method and could permit future development of noninvasive PCA using fentanyl. The terminal half-life estimated from the iontophoresis transdermal method is less than that from passive transdermal delivery of fentanyl,<sup>24</sup> suggesting that there may be minimal skin depot effect using iontophoresis. Further research into the pharmacokinetics and analgesic efficacy of this experimental technique is required before its introduction into clinical use.

### Systemic Administration: Transmucosal

The application of opioids to mucosal surfaces to achieve an effect is not a new concept. For centuries, this route has been used to self-administer opium. In current clinical settings, fentanyl had been delivered

across oral and nasal mucosal membranes to achieve effective analgesia.<sup>101,102</sup>

#### Oral Transmucosal Administration

Oral transmucosal fentanyl citrate (OTFC) incorporates fentanyl citrate in a candy mixture shaped into a lozenge on a stick. The citrate salt of fentanyl is soluble in both water and several candy matrices, and it is resistant to heat, which allows it to be incorporated into a buccal lozenge system. Oral transmucosal fentanyl citrate has been assessed thoroughly as a preoperative medication in children,<sup>103–107</sup> and it has produced dose-dependent increases in sedation and analgesia in adult volunteers.<sup>108</sup>

**Pharmacokinetics.** With oral transmucosal administration, fentanyl can be absorbed directly into systemic circulation through the oral mucosa or swallowed in saliva and absorbed through the gastrointestinal tract. Fentanyl absorbed through the latter route undergoes moderate first-pass extraction in the liver. Thus, the amount of saliva swallowed before adequate exposure of fentanyl to mucosal surfaces is critical in overall absorption and probably accounts for much of the interpatient variability associated with OTFC delivery.<sup>109</sup>

The pharmacokinetics of OTFC have been determined in volunteers.<sup>109</sup> Within doses ranging from 200–1,600  $\mu$ g, OTFC exhibits dose-proportional pharmacokinetic

§ Streisand JB, Busch MA, Gaylord BL, Gay MA, East KA: Dose proportionality of oral transmucosal fentanyl citrate in human volunteers (Abstract). *ANESTHESIOLOGY* 1996; 85:A322.

ics. In a study comparing oral administration of fentanyl with OTFC,<sup>109</sup> volunteers were given the same fentanyl dose (15  $\mu\text{g}/\text{kg}$ ) orally or transmucosally. The OTFC was placed in the buccal pouch and consumed in 15 min. The peak fentanyl  $C_p$  was two times greater with OTFC than with oral administration ( $3 \pm 1$  vs.  $1.6 \pm 0.6$  ng/ml) and was achieved earlier ( $23 \pm 3.4$  vs.  $101.3 \pm 48.8$  min).<sup>109</sup> Bioavailability with OTFC was 46–52%,<sup>109</sup> compared with 32% with oral administration. Fentanyl  $C_p$  decreased to less than 1 ng/ml within 75–135 min of initial mucosal exposure to OTFC. The speed of this decrease in concentration and the comparability of terminal half-life values after intravenous and OTFC administration suggest that a fentanyl depot does not develop in the oral mucosa.<sup>109</sup>

**Dose Requirements.** Only a few studies have investigated the use of OTFC in postoperative settings.<sup>101,110</sup> In a double-blind, randomized controlled trial,<sup>101</sup> OTFC (7–10  $\mu\text{g}/\text{kg}$ ) was administered three times at 4-h intervals on the first postoperative day in adult patients undergoing hip or knee arthroplasty. Patient-controlled analgesia morphine supplementation was available to patients in both OTFC and control groups, as needed. The OTFC dose per treatment averaged 9.7  $\mu\text{g}/\text{kg}$ . Similar VAS pain scores (VAS 2 or 3) were achieved with the two modalities, at approximately half the supplemental PCA dose in the OTFC group. Another double-blind, randomized trial<sup>110</sup> conducted in patients undergoing lower abdominal surgery showed that a single dose of 800  $\mu\text{g}$  OTFC provided better and more sustained analgesia than a dose of 200  $\mu\text{g}$ , with an onset and duration of effect similar to those achieved with a single intravenous bolus of 10 mg morphine.

**Analgesic Efficacy.** The median time to onset of analgesia with OTFC is approximately 4 min.<sup>110</sup> The duration of effect varies by patient, and doses used, ranging from  $159 \pm 91$  min with a dose of 200  $\mu\text{g}$  to  $220 \pm 112$  min with a dose of 800  $\mu\text{g}$ .<sup>110</sup> The quality of analgesia is good, as indicated by reported VAS pain scores of 2 or 3.<sup>101</sup> A single 800- $\mu\text{g}$  dose of OTFC results in an onset, duration, and quality of analgesia comparable to those of a single, intravenous 10-mg bolus of morphine in patients experiencing mild to moderate postoperative pain.

**Side Effects.** The incidence of adverse effects with OTFC supplemented by PCA morphine appears to be comparable to that with PCA morphine alone. Pruritus, nausea, and vomiting have been reported in 20%, 40%, and 13% of patients, respectively, using OTFC plus PCA morphine and 8%, 46%, and 15% with PCA morphine alone.<sup>101</sup> Similarly, episodes of hemoglobin oxygen desaturation to less than 90% with OTFC and PCA morphine alone are 13% and 31%, respectively ( $P$  value not significant).

Oral transmucosal fentanyl citrate appears to provide analgesia of rapid onset and medium duration, comparable to that achieved with an intravenous bolus of morphine. Despite a reduction in supplemental morphine consumption, the use of OTFC did not decrease the incidence of adverse events. With limited data on the use of OTFC in the postoperative period, its role as a useful postoperative analgesic technique is not well defined.

#### *Intranasal Administration*

The surface area of the nasal cavity in a normal adult is approximately 180  $\text{cm}^2$ , and the entire cavity is highly vascularized, with blood flow of  $40 \text{ ml} \cdot \text{min}^{-1} \cdot 100 \text{ g}^{-1}$  of tissue.<sup>111</sup> Although the pharmacokinetics of fentanyl *via* the intranasal route have not been evaluated, agents that are known to be lipophilic and have a low molecular weight (*e.g.*, propranolol) produce serum concentrations similar to those achieved with intravenous administration.<sup>112</sup> Thus, intranasal fentanyl might exhibit similar pharmacokinetic profiles.

**Dose Requirements.** The only two studies to date to establish a dose requirement for intranasal fentanyl compared the effects of intranasal and intravenous fentanyl in the 60 min immediately after surgery.<sup>102,113</sup> Fentanyl was administered with a metered device, with each spray delivering 4.5  $\mu\text{g}$  fentanyl. A dose of six sprays (27  $\mu\text{g}$  fentanyl) was delivered after various procedures and repeated every 5 min until patients were free of pain or refused any further analgesic. The same dose regimen was administered intravenously to the control group. An average of 3.9 nasal doses (range, 1–9 doses) of 27  $\mu\text{g}$  each resulted in excellent VAS pain scores at rest in the immediate postoperative period. The mean dose requirement of  $106 \pm 60$   $\mu\text{g}$  did not differ from that in the intravenous group ( $99 \pm 60$   $\mu\text{g}$ ).

**Analgesic Efficacy.** Data from the same studies indicate mean times to onset and peak analgesic effect with intranasal fentanyl of  $16.0 \pm 12.6$  min and  $26.3 \pm 15$  min (mean  $\pm$  SD), respectively, which are both slower than the times achieved with intravenous administration

|| Dsida R, Wheeler M, Birmingham P, Henthorn T, Avram M, Klein C, Coté C: A kinetic comparison: intravenous vs oral transmucosal fentanyl in tonsillectomy patients (Abstract). ANESTHESIOLOGY 1996; 85: A1073.

**Table 6. Pharmacokinetic Data of Five Sequential Doses of 4,000  $\mu\text{g}$  Liposomal-encapsulated Fentanyl at 12-h Interval**

	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5
$T_{\text{max}}$ (min)	16.7 $\pm$ 6.9	12.5 $\pm$ 6.3	19.2 $\pm$ 18.8	14.2 $\pm$ 8.4	18.3 $\pm$ 12.5
$C_{\text{max}}$ (ng/ml)	2.64 $\pm$ 0.88	2.92 $\pm$ 1.4	3.3 $\pm$ 1.45	3.48 $\pm$ 1.09	3.54 $\pm$ 1.15
$C_{\text{min}}$ (ng/ml)	0.6 $\pm$ 0.33	1.2 $\pm$ 0.6	1.5 $\pm$ 0.86	1.39 $\pm$ 0.46	0.93 $\pm$ 0.26

$T_{\text{max}}$  = time to reach peak plasma concentration of fentanyl;  $C_{\text{max}}$  = peak plasma concentration of fentanyl;  $C_{\text{min}}$  = minimum plasma concentration of fentanyl. Adapted with permission from Hung.<sup>120</sup>

(10.8  $\pm$  9 min and 20.2  $\pm$  12 min, respectively). In part, the slow onset time with intranasal administration may have resulted from the study design with small, incremental doses. The maximum pain-relieving effect was the same with both techniques.

**Side Effects.** Intranasal fentanyl did not irritate the nasal mucosa and produced only minimal respiratory effects (mild hemoglobin desaturation in 1 of 53 patients) and an incidence of nausea, vomiting, and euphoria less than 1%.

The value of intranasal administration of fentanyl for postoperative analgesia needs to be further defined. Based on only two studies, it appears that intranasal delivery of fentanyl can produce analgesia similar to that achieved by intravenous administration. However, use of a low dose slows onset time.

### Systemic Administration: Transpulmonary

Transpulmonary (inhalational) administration of medication produces rapid, effective drug delivery as a result of the thin alveolar-blood barrier, high tissue perfusion, and enormous surface area of the lungs. Delivery of morphine through the pulmonary system has proved effective.<sup>114,115</sup> Fentanyl also can produce postoperative analgesia if administered as a nebulized aerosol.<sup>116,117</sup> To overcome fentanyl's short duration of action, a liposome-encapsulated drug carrier system has been developed. Liposomes are microscopic vesicles composed of an aqueous compartment surrounded by a phospholipid bilayer that acts as a permeable barrier to entrap molecules.<sup>118</sup> Incorporation of a drug within a liposome provides a controlled, sustained release system.

#### Pharmacokinetics

Data on the pharmacokinetics of transpulmonary fentanyl are limited. Inhalation of 300  $\mu\text{g}$  fentanyl from the nebulizer produces a peak  $C_p$  of 0.4 ng/ml at 2 min and a plateau  $C_p$  of 0.1 ng/ml at 15 min. With inhalation of 100  $\mu\text{g}$ , fentanyl  $C_p$  remains stable at a concentration close to the detection limit of 0.02 ng/ml.<sup>116</sup>

In a study comparing nebulizer and intravenous administration of fentanyl,<sup>119</sup> delivery of 2,000  $\mu\text{g}$  of a nebulized mixture of free (50%) and liposomal-encapsulated (50%) fentanyl (FLEF) to volunteers resulted in a peak  $C_p$  of 1.15 ng/ml at 22 min. Although venous blood was sampled in this study, this should be of little consequence because, at 22 min, arterial and venous concentrations differ minimally. One important feature of the FLEF was that the  $C_p$  decreased slowly after the single 2,000- $\mu\text{g}$  dose: At 8 and 24 h after inhalation, fentanyl  $C_p$  values were 0.25  $\pm$  0.14 ng/ml and 0.12  $\pm$  0.16 ng/ml, respectively.

In a subsequent study,<sup>120</sup> five doses of 4,000  $\mu\text{g}$  FLEF were administered at 12-h intervals. The time to reach the peak concentration after each administration ranged from 12.5–19.2 min, and the fentanyl  $C_p$  was maintained within the analgesic therapeutic concentration; that is, 0.6–3 ng/ml (table 6). The bioavailability of inhaled FLEF is 12–20%,<sup>119,120</sup> which is consistent with the bioavailability of most drugs administered *via* the pulmonary system (10–20%).<sup>121</sup>

**Dose Requirements.** A dose of 300  $\mu\text{g}$  fentanyl administered *via* an oxygen-driven nebulizer significantly decreases pain after various surgical procedures.<sup>116</sup> It also significantly increases the median time to the first supplemental dose of parenteral morphine relative to control (190 *vs.* 9 min, respectively). However, in another study in which a single nebulized dose of 3 ml fentanyl citrate solution of different concentrations (100, 250, and 500  $\mu\text{g}/\text{ml}$ ) administered progressively in 9 min, only the highest dose (500  $\mu\text{g}/\text{ml}$ ) resulted in a moderate analgesic response within 5 min of inhalation.<sup>117</sup> The differences in these results probably can be accounted for by differences in study design, nebulizer administration technique, and surgical population. No studies have reported the dose requirements for inhaled liposomal-encapsulated fentanyl in patients after operation.

**Analgesic Efficacy.** After inhalation of nebulized fentanyl, moderate analgesia is achieved in 5 min,<sup>117</sup> the time when  $C_p$  peaks.<sup>116</sup> However, this analgesic effect

## FENTANYL AND ACUTE PAIN MANAGEMENT

lasts only 2 h. The FLEF mixture has the potential to prolong the analgesia, as indicated by the presence of a therapeutic concentration 12 h after inhalation of a single dose of 4,000  $\mu\text{g}$ .<sup>119</sup>

**Side Effects.** No clinically significant respiratory depression or evidence of respiratory tract irritation has been reported in the few patients studied thus far, nor is there any significant difference in nausea and drowsiness relative to controls.

Inhalation of fentanyl offers an easy, noninvasive route of administration. Onset of effect is rapid after nebulizer administration of fentanyl at a high dose (1,500  $\mu\text{g}$ ). However, the duration of action with this technique is too brief for routine clinical use. The liposome-encapsulated method significantly prolongs the effect of fentanyl, but it slows the onset of analgesia. Additional study is required to determine the safety and efficacy of transpulmonary fentanyl administration for postoperative analgesia.

### Neuraxial Administration

Epidural and intrathecal administration of fentanyl are long-established routes for intraoperative anesthesia and postoperative analgesia. The pharmacokinetics of epidural delivery have been well-studied, but relatively little is known about the systemic kinetics of intrathecal fentanyl.

#### Pharmacokinetics

The main routes of distribution after administration of fentanyl into the epidural space include (1) movement across the meninges into the cerebrospinal fluid (CSF); (2) movement from the CSF into the opioid receptor or other nonspecific binding site in the spinal cord; (3) rostral migration *via* the CSF to supraspinal sites; (4) vascular absorption in the epidural or spinal vascular system; and (5) uptake into epidural fat.

Factors that affect dural penetration include lipid solubility, molecular weight, molecular shape, and the degree of molecule ionization.<sup>122-124</sup> Lipid solubility, as assessed by the octanol-buffer partition coefficient, correlates with the permeability coefficient in a nonlinear manner. The optimal octanol-buffer distribution coefficient that results in maximal meningeal permeability lies between 129 (alfentanil) and 560 (bupivacaine).<sup>123</sup> This relation between lipid solubility and the meningeal permeability coefficient of a drug can be explained by the dual nature of the

arachnoid mater, which is the principal meningeal permeability barrier.<sup>123</sup> To cross the arachnoid mater, a drug molecule must diffuse through the hydrophilic domain (*e.g.*, extracellular and intracellular fluid) and hydrophobic domain (*e.g.*, cell membrane lipids). Lipophilic drugs readily dissolve in the lipophilic component of the arachnoid mater and thus cross the region easily. The hydrophilic zone is more difficult for these drugs to penetrate, creating the rate-limiting factor for diffusion *via* the arachnoid membrane. As a result, membrane permeability is highest in the opioids having intermediate lipid solubility (*e.g.*, fentanyl).

Because of its high octanol-buffer partition coefficient, fentanyl also has high vascular permeability and moves as easily into the intravascular compartment as into the subarachnoid compartment. The extent of vascular absorption is influenced by various factors, including dose administered, the mode of administration (bolus *vs.* infusion), and, possibly, concurrent use of epinephrine.

After epidural bolus administration, systemic absorption of fentanyl increases as the bolus dose increases. For example, administration of a bolus of 30–70  $\mu\text{g}$  ( $\sim$  0.5–1  $\mu\text{g}/\text{kg}$ ) results in a peak fentanyl  $C_p$  less than 0.2 ng/ml in the first 30 min,<sup>125,126</sup> which is much less than the range for MEC. However, within 10–30 min of an epidural bolus of 100–200  $\mu\text{g}$  ( $\sim$  1.5–3 g/kg), the plateau systemic concentration is 0.3–0.86 ng/ml,<sup>41,126-128</sup>; that is, it is within the range of the MEC.

With continuous epidural infusion of fentanyl, clearance from the blood determines the blood concentration at steady state. Continuous infusion of doses resulting in good analgesia produces significant fentanyl  $C_p$  (1 or 2 ng/ml) after several hours of administration.<sup>18,19,38,39,129,130</sup> Studies comparing therapeutic doses of epidural and intravenous fentanyl for postoperative pain relief show similar fentanyl  $C_p$  values at equal and equianalgesic doses (table 7A).<sup>18,19,38,39</sup> With thoracic epidural administration (*i.e.*, thoracotomy), dose requirements<sup>17,131</sup> and  $C_p$ <sup>17</sup> are lower compared with lumbar epidural administration, but systemic absorption remains significant.<sup>17</sup> There are no published data on the pharmacokinetics of fentanyl in CSF with continuous epidural infusion or repeated bolus administration (patient-controlled epidural analgesia [PCEA]).

Adding 1:300,000 epinephrine to a continuous thoracic epidural infusion of fentanyl significantly reduces the fentanyl  $C_p$  and, relative to intravenous delivery, the equianalgesic dose.<sup>132</sup> This effect may be caused by a

Table 7. Prospective, Randomized Clinical Studies Comparing the Use of Fentanyl *via* Different Routes

Study	Site of Epidural	Surgery	Analgesia	Plasma Concentration	Respiratory Side Effects*	Other Side Effects	Dose Requirement
Epidural vs. intravenous							
Ellis <sup>38</sup>	L	C-section	NSD	NSD (24 h)	NSD	NSD	NSD
Loper <sup>39</sup>	L	Knee	NSD	NSD	NSD	NSD	NSD
Glass <sup>19</sup>	L	Lower abdomen/ extremity	NSD	NSD	NSD	NSD	NSD
Cooper <sup>67</sup>	L	C-section	EP > IV	N/A	NSD	NSD	NSD
Grant <sup>55</sup>	L	Thoracotomy	NSD	N/A	NSD	NSD	28% ↓ inEp
Sandler <sup>18</sup>	L	Thoracotomy	NSD	NSD	NSD	NSD	25% ↑ inEp
Guinard <sup>52</sup>	L	Thoracotomy	NSD	N/A	NSD	Pr-NSD N (IV > Ep)	NSD
Baxter <sup>150</sup>	L	Thoracotomy	NSD	NSD	NSD	NSD	NSD
Salomaki <sup>17</sup>	T	Thoracotomy	NSD	EP < IV	IV > EP	NSD except N,S(IV > Ep)	43% ↓ inEp
Welchew <sup>57</sup>	T	Upper abdominal	NSD	N/A	N/A	NSD	55% ↓ inEp
Guinard <sup>52</sup>	T	Thoracotomy	NSD	N/A	NSD	Pr-NSD N (IV > Ep)	NSD
Thoracic vs. lumbar epidural							
Coe <sup>149</sup>	—	Thoracotomy	NSD	N/A	NSD	NSD	NSD
Guinard <sup>52</sup>	—	Thoracotomy	NSD	N/A	NSD	NSD	NSD
Sawchuck <sup>131</sup>	—	Thoracotomy	NSD	N/A	L > Th	NSD	NSD
Bouchard <sup>160</sup>	—	Thoracotomy	NSD	NSD	NSD	NSD	NSD

NSD = no significant difference throughout the whole study period; N/A = not available; L = lumbar epidural; Th = thoracic epidural; Pr = pruritus; N = nausea and vomiting; S = sedation; Ep = epidural group; IV = intravenous group; Dose requirement = either presented as cumulative dose or average infusion rate.

\* Clinically significant respiratory depression: defined as respiratory depression requiring intervention *i.e.*, naloxone administration, resuscitation, or cessation of fentanyl treatment.

reduction in vascular uptake resulting from vasoconstriction or by a direct  $\alpha$ -agonist activity of epinephrine.<sup>133</sup>

Once in the CSF, fentanyl, similar to other opioids, spreads rostrally. The CSF concentration at the level of the cervical spine peaks within 20 min,<sup>125</sup> compared with 3 h for morphine<sup>134</sup> and 1 h for meperidine.<sup>135</sup> Because of the high affinity of fentanyl with nonspecific binding sites in the lipid-rich spinal cord,<sup>136</sup> only a small proportion (~10%) of the administered dose migrates to the cervical region.<sup>125</sup>

Fentanyl also can migrate from the CSF into the epidural vascular compartment *via* the dura. However, little is known about the systemic pharmacokinetics of intrathecal fentanyl. At an average intrathecal infusion rate of  $0.8 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$  after thoracotomy, vascular absorption is significant and fentanyl  $C_p$  values range from 0.49–0.72 ng/ml.<sup>137</sup> However, this range reflects  $C_p$  values much lower than plasma analgesic concentrations when intravenous fentanyl infusion is used for post-thoracotomy analgesia (1.4–1.6 ng/ml).<sup>17,18</sup> This differ-

ence suggests that analgesic effect is mediated in part at the spinal level.

#### Epidural Administration

More than 40 published clinical trials document epidural fentanyl administration and effect. Most suggest that epidural fentanyl is less likely than morphine to produce clinically significant ventilatory depression.<sup>138</sup> However, respiratory arrest has been reported.<sup>139</sup> Fentanyl is reported to be associated with fewer minor adverse effects (nausea, vomiting, pruritus, sedation, urinary retention).<sup>140,141</sup> The modes of epidural administration are the same as those used intravenously, *i.e.*, bolus dose alone, bolus dose combined with continuous infusion, continuous infusion alone, PCEA, and PCEA with a continuous fixed or variable background infusion. Both trauma and postsurgical populations have been studied, including patients with fractured ribs,<sup>142</sup> those recovering from abdominal<sup>19,127,143–147</sup> and orthopedic surgery,<sup>39,129</sup> cesarean section,<sup>38,148</sup> thoracoto-

## FENTANYL AND ACUTE PAIN MANAGEMENT

my,<sup>17,18,52,130,131,149-153</sup> and radical prostatectomy.<sup>154</sup> In addition, epidural fentanyl often is combined with local anesthetic agents (particularly bupivacaine) and other adjuvant drugs (epinephrine, clonidine, other opioids) to provide postoperative analgesia, pain control for labor and delivery, and relief from perioperative cesarean section pain. These combined techniques are not discussed in this review.

**Dose Requirements.** The dosage of fentanyl used for repeated single bolus administration varies from 50 to 200  $\mu\text{g}$  (approximately 1-3  $\mu\text{g}/\text{kg}$ ,<sup>127,143,155,156</sup>) and up to 5  $\mu\text{g}/\text{kg}$ .<sup>157</sup> Analgesia begins within 15 min and lasts 2 to 4 h.<sup>126,127,143,155,157</sup> Increasing the diluent volume to 10-25 ml<sup>155</sup> and using a concentration of 10  $\mu\text{g}/\text{ml}$ <sup>158</sup> speeds onset time and increases the duration of action. However, the duration of analgesia provided by a bolus dose of fentanyl is brief, making administration by infusion necessary for adequate postoperative pain relief.

Epidural infusion rates range from 0.5-2.5  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ . Epidural or intravenous bolus opioid (usually fentanyl) supplementation may be used to achieve or maintain good analgesia, especially if the infusion rate is fixed.<sup>52,144</sup> In addition, PCEA has been used after operation, often with a background infusion, but in some cases alone.<sup>19,67,147,159-161</sup> Doses of 20-25  $\mu\text{g}$  with a lockout interval of 6-10 min and background infusion rates of 0.5-1  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$  are most common. Variability in dose requirements, particularly in the first 24 h after operation, may be associated with differences in anesthetic technique (e.g., epidural *vs.* general anesthesia), intraoperative opioid administration, the magnitude of postoperative pain after different surgical procedures, or all of these.<sup>162</sup>

**Analgesic Efficacy.** Continuous epidural fentanyl infusion, PCEA, or both provide excellent analgesia and overcome the limitations to the duration of action associated with epidural bolus administration. Although analgesia is excellent at rest, pain scores increase with movement and coughing.<sup>39,52,127,152,154,157</sup> This is in contrast to the good analgesia at rest and with ambulation or coughing provided by intrathecal administration of fentanyl.<sup>137,163</sup>

Several investigators have compared the efficacy of intravenous and epidural fentanyl in a series of controlled trials conducted in different postoperative patient populations.<sup>18,19,38,39,52,55,57,67,150</sup> Whether the two techniques provide equivalently effective analgesia is controversial. To put the argument in perspective, several parameters are required for comparison: analgesic effect, dose requirement,  $C_p$ , and respiratory and non-

respiratory side effects. Equally important are the site and type of surgery and the site of epidural catheterization (*i.e.*, lower abdominal or orthopedic surgery using a lumbar epidural catheter,<sup>19,38,39,67</sup> upper abdominal surgery or thoracotomy using a lumbar epidural catheter,<sup>18,52,53,150</sup> or upper abdominal surgery or thoracotomy using a thoracic epidural catheter [table 7A]).<sup>17,52,57</sup>

Intravenous and epidural fentanyl provide equivalent analgesia in these surgical populations. Dose requirements are similar with the two modes of administration (e.g., a bolus plus infusion or PCEA). However, some investigators report that placing the catheter at a dermatomal level corresponding to the surgical site (thoracic placement for thoracotomy<sup>17</sup> and upper abdominal surgery<sup>57</sup>) decreases the hourly and cumulative dose requirement for epidural delivery by 50% compared with intravenous. In contrast, other investigators report no significant differences in the analgesic dose requirements associated with thoracic *versus* lumbar epidural catheters for upper abdominal or thoracic surgery (table 7B).<sup>52,131,149,160</sup> Similarly, neither the fentanyl  $C_p$  associated with analgesia nor the side effect profiles for the two techniques differ significantly. Overall, these findings indicate little clinical advantage to providing postoperative analgesia by the epidural rather than intravenous route of administration.

**Side Effects.** Most reviews of the nonrespiratory side effects of intrathecal and epidural opioids focus on morphine.<sup>164-166</sup> With epidural fentanyl, the most common side effect is pruritus, with an incidence of 0-85%. It usually appears within an hour after bolus epidural injection and lasts 20-30 min. Fentanyl-induced pruritus does not appear to be related to histamine release and can be antagonized with naloxone.<sup>164</sup> Features that distinguish epidural fentanyl-induced pruritus from that resulting from epidural morphine include diminished intensity<sup>140</sup> and localized (segmental or regional) effect. The facial area rarely is involved.<sup>141,167</sup> Cutaneous flare and urticaria are uncommon.<sup>140,141</sup> Treatment is rarely necessary.

The incidence of nausea and vomiting with epidural fentanyl is approximately 20-30%, which is comparable to other epidural opioids.<sup>166</sup> Nausea usually occurs within 3 h of fentanyl administration.<sup>140</sup> Treatment with antihistaminic agents, opioid agonist or antagonists, or pure opioid antagonists is common.<sup>160,168</sup>

Epidural opioids can produce dose-independent, naloxone-reversible urinary retention. The mechanism of this effect is believed to be secondary to the interaction of epidural opioids with opioid receptors in the sacral



Table 8. Epidural Fentanyl Studies: Respiratory Side Effects

Study	Dosage	Respiratory Depression Parameter/Measurement	CSRD	%
Carrie <sup>191</sup>	B-150-200 µg	SRR	No	0
Lomesey <sup>127</sup>	B-200 µg	SRR, Pa <sub>CO2</sub>	No	0
Robertson <sup>167</sup>	B-100 µg×2	SRR	No	0
Ahuja <sup>179</sup>	B-1.5 µg/kg; I-0.5 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, Pa <sub>CO2</sub>	No	0
Negre <sup>41</sup>	B-200 µg	SRR, VE, ET <sub>CO2</sub>	No	0
Renaud <sup>129</sup>	B-1 µg/kg; I-1 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, VE, ET <sub>CO2</sub>	No	0
Chrubasik <sup>146</sup>	B-100 µg; I-200 µg/h	SRR, Pa <sub>CO2</sub>	No	0
Gough <sup>128</sup>	B-1.5 µg/kg; I-0.6 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR	No	0
Kreitzer <sup>192</sup>	B-100 µg, I-1.3 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR	No	0
Melendez <sup>151</sup>	B-200 µg (repeated)	SRR, Pa <sub>CO2</sub>	No	0
Badner <sup>130</sup>	B-1.5 µg/kg; I-1.47 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, AP, Pa <sub>CO2</sub>	No	0
Ellis <sup>38</sup>	B-1.5 µg/kg; I-1.52 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, ET <sub>CO2</sub>	No	0
Loper <sup>39</sup>	I-100 µg/h	SRR	No	0
Salomaki <sup>17</sup>	B-variable; I-0.95 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, Pa <sub>CO2</sub> , AP	No	0
Coe <sup>149</sup>	B-1.5 µg/kg; I-0.57-0.69 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR	No	0
Grant <sup>55</sup>	PCEA: B-50 µg; I-0.75-2 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, Pa <sub>CO2</sub>	No	0
White <sup>140</sup>	B-40-100 µg; I-20-80 µg/h	SRR, Pa <sub>CO2</sub>	No	0
Guinard <sup>52</sup>	I-1.15-1.22 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, AP, SP <sub>O2</sub> , Pa <sub>CO2</sub>	No	0
Sandler <sup>18</sup>	B-0.5-1.5 µg/kg; I-1.95 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, AP, Pa <sub>CO2</sub>	No	0
Sawchuck <sup>131</sup>	B-25-50 µg; I-1.55-2.06 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, Pa <sub>CO2</sub>	4/30	13%
Owen <sup>147</sup>	(1) PCEA: B-25 µg, LO-15 min (2) PCEA as 1 plus I-50 µg/h (3) I-50 µg/h ± B-25 µg	Sp <sub>O2</sub> < 94%, Sp <sub>O2</sub> < 85%	No	0
Benzon <sup>152</sup>	I-60-63 µg · kg <sup>-1</sup> · h <sup>-1</sup>	SRR, Pa <sub>CO2</sub> , Sp <sub>O2</sub>	No	0
Geller <sup>144</sup>	B-60 µg; I-20 µg/h	SRR, Pa <sub>CO2</sub>	No	0
Baxter <sup>150</sup>	b-1.5 µg/kg; I-1 µg · kg <sup>-1</sup> · h <sup>-1</sup> *	SRR, AP, Sp <sub>O2</sub>	7/25	28%
Salomaki <sup>193</sup>	I-20-100 µg/h	Pa <sub>CO2</sub> , SRR	No	0
Bouchard <sup>160</sup>	PCEA: B-25 µg; LO-10 min	SRR	No	0
Cooper <sup>67</sup>	PCEA: B-20 µg; LO-10 min	SRR	No	0
Joshi <sup>194</sup>	B-20 µg; I-8-20 µg/h	Not specified	No	0

B = bolus; I = infusion; PCEA = patient-controlled epidural analgesia; LO = lockout interval; SRR = respiratory rate <8-10; AP = apnea episode; Sp<sub>O2</sub> = desaturation <90%, Pa<sub>CO2</sub> - ↑ Pa<sub>CO2</sub> > 50 mmHg; CSRD = clinically significant respiratory depression: defined as respiratory depression requiring intervention, i.e. naloxone administration, resuscitation, or cessation of fentanyl treatment.

\* Morphine supplementation via patient-controlled analgesia.

spinal cord.<sup>169</sup> This interaction inhibits sacral parasympathetic neural outflow, relaxing the bladder detrusor muscle, increasing the maximum capacity of the bladder, thereby resulting in urinary retention.<sup>170,171</sup> The reported incidence of urinary retention ranges from 0-50% but is less than 12% in most studies. Data on the incidence of urinary retention after epidural fentanyl are limited by the common postoperative practice of placing or maintaining an indwelling urinary catheter.

Respiratory depression (table 8) is the most serious adverse effect of the use of epidural opioids. Various factors may contribute to its occurrence with epidural fentanyl, including the use of additional opioids or sedative drugs, antiemetics, or prolonged infusions.<sup>172,173</sup>

Initially, the lipophilic properties of fentanyl were thought to confer minimal risk of delayed respiratory depression due to poor cephalad spread in the CSF.

However, the single human CSF pharmacokinetic study of epidural fentanyl bolus administration at the lumbar level shows that maximum CSF concentrations in the cervical region are as much as 10% of CSF concentration in the lumbar region.<sup>125</sup>

Clinically significant respiratory depression can occur with either bolus doses or continuous infusions of epidural fentanyl. The carbon dioxide ventilatory response curve is depressed after an epidural bolus dose of 200 µg.<sup>41</sup> However, incidents of respiratory arrest<sup>139,174</sup> and profound respiratory depression<sup>175-178</sup> have been reported after a 100-µg dose. Epidural infusions of fentanyl ranging from 0.5-1 µg · kg<sup>-1</sup> · h<sup>-1</sup> depress the carbon dioxide ventilatory response curve.<sup>129,179</sup> Despite these data, clinically significant respiratory depression appears to be relatively rare with epidural fentanyl. Of those 29 studies with a total of approximately 600 patients that

## FENTANYL AND ACUTE PAIN MANAGEMENT

Table 9. Intrathecal Fentanyl Studies: Postoperative Analgesia

Study	Surgery	Mode/Bolus	Analgesia	Onset (O) (min)/Duration (D) (h)	Nausea Vomiting	Pruritus	CSRD
Jacobson <sup>183</sup>	Foot	Bolus 25 $\mu\text{g}$	Complete relief	O 5-10/D 4	None	None	None
Jacobson <sup>186</sup>	Postamputation (phantom limb pain)	Bolus 25 $\mu\text{g}$	Complete relief	O 5-10/D 8	None	Present*	None
Tobias <sup>184</sup>	Exploratory laparotomy	Infusion 0.2 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$	PS 0-1	—	None	None	None
Domsky <sup>182</sup>	Hip	PCA Bolus 6 $\mu\text{g}$ LO 1-1.5 h	VAS 5 (0-12 hr) VAS 3-5 (12-2 h) VAS 1-3 (24-48 h)	O 15	None	None	None
Honet <sup>188</sup>	1st stage labor	Bolus 10 $\mu\text{g}$ (15.5 $\pm$ 5.1 $\mu\text{g}$ )†	VAS 3-4	O 20/D 1.3	Present*	Present*	N/A
Reuben <sup>185</sup>	Lower extremity vascular surgery	Bolus 5 $\mu\text{g}$	VAS 5-7	N/A	0/10	0/10	None
		10 $\mu\text{g}$	VAS 3-7	O 2-3/D 1	0/10	1/10	
		20 $\mu\text{g}$	VAS 1-3	O 3-5/D 2	0/10	0/10	
		40 $\mu\text{g}$	VAS 0-2	O 2-3/D 5	0/10	1/10	
		50 $\mu\text{g}$	VAS 0-2	O 2-3/D 5	1/10	5/10	
Sudarshan <sup>166</sup>	Thoracotomy	Bolus 50-150 $\mu\text{g}$	VAS 1-2 (rest/movement)	O 60/D 4-10	None	3/10	None

VAS = visual analogue scale (0 = no pain; 10 = worst imaginable pain); PS = Hannallah-Rice-Broadman (OPS) scale: a scoring system from 0-10;<sup>195</sup> LO = lockout interval; N/A = not available; CSRD = clinically significant respiratory depression defined as respiratory depression requiring intervention, e.g. naloxone treatment, resuscitation, or cessation of fentanyl treatment.

\* Side effect occurred but severity or incidence not recorded.

† Average first dose.

evaluated the incidence and severity of respiratory side effects, the overall incidence of clinically significant depression is approximately 1.8%. All these incidences of respiratory depression occurred in two of the studies.<sup>131,150</sup> In one study,<sup>131</sup> administration of fentanyl through a thoracic or lumbar catheter at an average infusion rate of 1.55-2.06  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$  resulted in respiratory depression requiring naloxone intervention in 4 of 30 patients. In the other study,<sup>150</sup> it is difficult to assess the clinical significance of the respiratory depression because the protocol demanded arterial blood gas sampling every 2 h and administration of naloxone to each patient in whom the partial pressure of carbon dioxide in arterial blood exceeded 50 mmHg (7 of 25 patients), regardless of clinical status.

Epidural administration of fentanyl can provide good to excellent postoperative analgesia. Bolus administration produces a rapid onset but short duration of effect. A continuous infusion or PCEA is therefore more common in the postoperative setting and provides excellent analgesia at rest. (As with other routes of administration, the analgesic effect diminishes with movement and coughing.) Compared with intravenous administration,

the analgesic efficacy, dose requirement,  $C_p$ , respiratory and nonrespiratory side effects of epidural and intravenous fentanyl are similar, indicating no advantage to using epidural rather than intravenous fentanyl infusion alone for postoperative analgesia.

#### Intrathecal Administration

Intrathecal fentanyl usually is combined with local anesthetic agents for perioperative anesthesia and analgesia, particularly in obstetric patients.<sup>180,181</sup> Only a limited number of reports, many of them single cases, document the use of intrathecal fentanyl alone for postoperative analgesia<sup>182-184</sup> (table 9). Modes of administration include single bolus injection,<sup>183,185,186</sup> intrathecal catheterization, repeated observer-administered or PCA boluses,<sup>163,181</sup> and continuous infusion *via* an intrathecal catheter.<sup>137,184,187</sup> Repetitive bolus injection of fentanyl *via* an intrathecal catheter also has been assessed as the sole source of analgesia during the first stage of labor.<sup>188</sup>

**Dose Requirements.** The minimum intrathecal bolus requirement for postoperative analgesia is 20  $\mu\text{g}$ .<sup>185</sup> In obstetric patients, a smaller dose (10  $\mu\text{g}$ ) is effective

(table 9). Onset of analgesia is usually within 5–15 min, but duration is variable, ranging from 1–5 h in most reports. Intrathecal fentanyl has also been administered as PCA *via* an intrathecal catheter. Although the ideal bolus size and lockout interval for intrathecal fentanyl *via* PCA remain unknown, good analgesia with no clinically significant adverse effects can be achieved with bolus doses of 6  $\mu\text{g}$  and a lockout interval of 1–1.5 h.<sup>182</sup>

At an average infusion rate of  $0.8 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ , continuous intrathecal infusion produces satisfactory analgesia in patients having thoracotomy.<sup>137</sup> A rate of 5  $\mu\text{g}/\text{h}$  (*i.e.*, approximately  $0.065 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ ) in a similar surgical population resulted in inadequate postoperative analgesia and the need for parenteral opioid supplementation in nearly all patients.<sup>187</sup>

**Analgesic Efficacy.** Effective postoperative analgesia can be achieved with intrathecal bolus doses of 20  $\mu\text{g}$  (table 9). Increasing this dose to 50  $\mu\text{g}$  produces excellent analgesia at rest, neutralizes the effects of ambulation or coughing on the quality of analgesia in patients after thoracotomy, and improves postoperative pulmonary function compared with PCA morphine alone.<sup>163</sup> Similar analgesic efficacy also can be achieved with an intrathecal infusion at  $0.8 \mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ ,<sup>137</sup> which also overcomes the painful effects of movement and coughing with greater speed than thoracic epidural or intravenous fentanyl at infusion rates of 1.22 and 1.27  $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$ , respectively.<sup>50</sup> Thus, the intrathecal route provides better and more complete analgesia than fentanyl administered by other modalities that rarely provide dense analgesia with movement or coughing. A potential limitation to the use of the intrathecal technique is the need for an indwelling intrathecal catheter, which confers the risk for infection or neurotoxic effects (with local anesthetic agents), and necessitates clinical expertise in catheter placement and maintenance.

**Side Effects.** Side effects are relatively minor with intrathecal fentanyl, and only a few studies report any incidence of nausea or mild-to-moderate pruritus. However, these symptoms develop with both relatively large bolus doses (*e.g.*, a 50- $\mu\text{g}$  bolus dose) and low-dose infusions (*e.g.*, 5  $\mu\text{g}/\text{h}$  for 24 h; table 9). A 30% incidence of urinary retention has been reported at a low-dose continuous infusion of 5  $\mu\text{g}/\text{h}$  progressively in 24 h.<sup>187</sup>

Clinically significant respiratory depression has not been reported with the use of intrathecal fentanyl (table 9), even at total doses as high as 100  $\mu\text{g}$  delivered directly into the subarachnoid space.<sup>163</sup> In contrast, the same dose of fentanyl (100  $\mu\text{g}$ ) delivered epidurally has been associated with severe respiratory depression. Sev-

eral explanations may account for this difference in effect. First, intrathecal administration results in lower systemic absorption than does epidural delivery.<sup>137</sup> Second, the intrathecal dose requirement generally is lower than the epidural requirement, which further reduces the risk of dose-related ventilatory depression. Finally, studies of intrathecal fentanyl administration involve only small numbers of patients, potentially making it difficult to detect a statistically significant incidence of respiratory depression.

Compared with epidural administration, fentanyl delivery *via* the intrathecal route provides more intense and complete analgesia at rest and with movement, at a lower dose requirement than either the epidural or intravenous routes. Vascular absorption occurs but to a lesser extent. However, the requirement of an indwelling intrathecal catheter introduces the risk for infection or neurotoxic effects, limiting the popularity of this technique for use after operation.

## Conclusions

Fentanyl is used widely as an analgesic agent in the postoperative or critically ill patient. Because of its physical properties and potency, it is effective *via* multiple routes of administration; noninvasive routes are being developed. Subarachnoid use provides the most intense, complete analgesia, although intravenous PCA, with its more convenient format, also is effective. Adverse effects are apparent with all modes of administration. Pruritus, urinary retention, and nausea and vomiting are common, and all patients receiving fentanyl for postoperative analgesia require vigilant monitoring to detect and treat respiratory effects. New experimental modalities, especially iontophoretic application and transmucosal delivery, present promising opportunities for postoperative analgesia.

The authors thank Christine Drane for preparing the manuscript, Winifred von Ehrenberg for editorial assistance, and Dr. Hossam El-Beheiry for advice to the manuscript.

## References

1. Andrews CJH, Prys-Roberts C: Fentanyl—A review. *Clin Anaesthesiol* 1983; 1:97–122
2. Stanley TH: The history and development of the fentanyl series. *J Pain Symptom Manage* 1992; 7:S3–7
3. Nilsson E: Origins and rationale of neurolept-analgesia. *ANESTHESIOLOGY* 1963; 24:267–8
4. Flacke JW, Kripke BJ, Bloor BC, Flacke WE: Comparison of opi-

## FENTANYL AND ACUTE PAIN MANAGEMENT

oids in balanced anesthesia, *Opioids in Anesthesia*. 1st edition. Edited by Estafanous FG. Stoneham, UK, Butterworth, 1984, pp 140-5

5. Bailey PL, Stanley TH: Narcotic intravenous anesthetics, *Anesthesia*. 3rd edition. Edited by Miller RD. New York, Churchill Livingstone, 1990, pp 281-366

6. Lunn JK, Stanley TH, Webster LR, Eisele J, Woodward A: High dose fentanyl anesthesia for coronary artery surgery: Plasma fentanyl concentration and influence of nitrous oxide on cardiovascular responses. *Anesth Analg* 1979; 58:390-5

7. Stanley TH, Berman L, Green O, Robertson D: Plasma catecholamine and cortisol response to fentanyl-oxygen anesthesia for coronary artery operations. *ANESTHESIOLOGY* 1980; 53:250-3

8. Meuldermans WEG, Hurkmans RMA, Heykants JJP: Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. *Arch Int Pharmacodyn* 1982; 257:4-19

9. Hug CC Jr: Pharmacokinetics of new synthetic narcotic analgesics, *Opioids in Anesthesia*. 1st edition. Edited by Estafanous FG. Stoneham, UK, Butterworth, 1984, pp 50-69

10. Cookson RF, Towse GDW: The search for new analgesics. *Clin Res Rev* 1981; 1:219-30

11. Beckett AH, Casey AF: Synthetic analgesics, stereochemical considerations. *J Pharm Pharmacol* 1954; 6:986-1001

12. Beckett AH: Analgesics and their antagonists: Some steric considerations. Part I. The dissociation constants of some tertiary amines and synthetic analgesics, the conformations of methadone-type compounds. *J Pharm Pharmacol* 1956; 8:848-59

13. Michiels M, Hendriks R, Heykants J: A sensitive radioimmunoassay for fentanyl-plasma level in dogs and man. *Euro J Clin Pharmacol* 1977; 12:153-8

14. Nimmo WS, Todd JG: Fentanyl by constant rate i.v. infusion for postoperative analgesia. *Br J Anaesth* 1985; 57:250-4

15. Lehmann KA, Heinrich C, van Heiss R: Balanced anesthesia and patient-controlled postoperative analgesia with fentanyl: Minimum effective concentrations, accumulation and acute tolerance. *Acta Anaesth Belg* 1988; 39:11-23

16. Rowbotham DJ, Wyld R, Nimmo WS: A disposable device for patient-controlled analgesia with fentanyl. *Anaesthesia* 1989; 44:922-4

17. Salomäki TE, Laitinen JO, Nuutinen LS: A randomized double-blind comparison of epidural versus intravenous fentanyl infusion for analgesia after thoracotomy. *ANESTHESIOLOGY* 1991; 75:790-5

18. Sandler AN, Panos L, Stringer D, Badner N, Friedlander M, Koren G, Katz J: A randomized, double-blind comparison of lumbar epidural and intravenous fentanyl infusions for post-thoracotomy pain relief: Analgesic, pharmacokinetic and respiratory effects. *ANESTHESIOLOGY* 1992; 77:626-34

19. Glass PSA, Estok P, Ginsberg B, Goldberg, JS, Sladen RN: Use of patient-controlled analgesia to compare the efficacy of epidural to intravenous fentanyl administration. *Anesth Analg* 1992; 74:345-51

20. Stoeckel H, Schuttler J, Magnussen H, Hengstmann JH: Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers. *Br J Anaesth* 1982; 54:1087-95

21. Cartwright P, Prys-Roberts C, Gill K, Dye A, Stafford M, Gray A: Ventilatory depression related to plasma fentanyl concentration during and after anesthesia in humans. *Anesth Analg* 1983; 62:966-74

22. Schuttler J, White PF: Optimization of the radioimmunoassays for measuring fentanyl and alfentanil in human serum. *ANESTHESIOLOGY* 1984; 61:315-20

23. Kowalski SR, Gourlay GK, Cherry DA, McLean CF: Sensitive gas

liquid chromatography method for the determination of fentanyl concentration in blood. *J Pharmacol Methods* 1987; 18:347-55

24. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR: Absorption characteristics of transdermally administered fentanyl. *ANESTHESIOLOGY* 1989; 70:928-34

25. Woestenborghs RJH, Stanski DR, Scott JC, Heykants JJP: Assay Methods for fentanyl in serum: Gas-liquid chromatography versus radioimmunoassay. *ANESTHESIOLOGY* 1987; 67:85-90

26. Glass PSA, Shafer SL, Jacobs JR, Reves JG: Intravenous drug delivery systems, *Anesthesia*. 4th edition. Edited by Miller RD. New York, Churchill Livingstone, 1994, pp 389-416

27. McClain DA, Hug CC: Intravenous fentanyl kinetics. *Clin Pharmacol Ther* 1980; 28:106-14

28. Hug CC, Murphy MR: Tissue redistribution of fentanyl and termination of its effects in rats. *ANESTHESIOLOGY* 1981; 55:369-75

29. Coda BA: *Opioids, Clinical Anesthesia*. 3rd edition. Edited by Barash PG, Cullen BF, Stoelting RK. Philadelphia, Lippincott-Raven, 1996, pp 329-58

30. Stanski DR, Hug CC Jr: Alfentanil—A kinetically predictable narcotic analgesic (editorial). *ANESTHESIOLOGY* 1982; 57:435-8

31. Mather LE: Clinical pharmacokinetics of fentanyl and its newer derivatives. *Clin Pharmacokinet* 1983; 8:422-6

32. Scott JC, Ponganis KV, Stanski DR: EEG quantitation of narcotic effect: The comparative pharmacodynamics of fentanyl and alfentanil. *ANESTHESIOLOGY* 1985; 62:234-41

33. Hill HF, Chapman CR, Saeger L, Bjurstrom R, Walter MH, Kippes M: Steady-state infusions of opioids in humans: II. Concentration-effect relationships and therapeutic margins. *Pain* 1990; 43:68-79

34. Andrews CJH, Sinclair M, Prys-Roberts C, Dye A: Ventilatory effects during and after continuous infusion of fentanyl or alfentanil. *Br J Anaesth* 1983; 55:211S-6S

35. Duthie DJR, McLaren AD, Nimmo WS: Pharmacokinetics and fentanyl during constant rate i.v. infusion for the relief of pain after surgery. *Br J Anaesth* 1986; 58:950-6

36. Hackl W, Fitzal S, Lackner F, Weindlmayr-Goettel M: Vergleich von Fentanyl und Tramadol zur Schmerzbehandlung mittels on-demand-analgesie-Computer in der frühen postoperativen Phase. *Anaesthesist* 1986; 35:665-71

37. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ: Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. *Anesth Analg* 1988; 67:329-37

38. Ellis DJ, Millar WL, Reisner LS: A randomized double-blind comparison of epidural versus intravenous fentanyl infusion for analgesia after cesarean section. *ANESTHESIOLOGY* 1990; 72:981-6

39. Loper KA, Ready B, Downey M, Sandler AN, Nessly M, Rapp S, Badner N: Epidural and intravenous fentanyl infusions are clinically equivalent after knee surgery. *Anesth Analg* 1990; 70:72-5

40. Austin KL, Stapleton JV, Mather LE: Relationship between blood meperidine concentrations and analgesic response: A preliminary report. *ANESTHESIOLOGY* 1980; 53:460-6

41. Negre I, Gueneron JP, Ecofey C, Penon C, Gross JB, Levron JC, Samii K: Ventilatory response to carbon dioxide after intramuscular and epidural fentanyl. *Anesth Analg* 1987; 66:707-10

42. Fung DL, Eisele JH: Narcotic concentration-respiratory effect curves in man. *ANESTHESIOLOGY* 1980; 53:3397

43. Glass PSA, Jacobs JR, Smith LR, Ginsberg B, Quill TJ, Bai SA, Reves JG: Pharmacokinetic model-driven infusion of fentanyl: Assessment of accuracy. *ANESTHESIOLOGY* 1990; 73:1082-90

44. Sandler AN: Opioid-induced respiratory depression in the post-

operative period. Management of postoperative pain. Edited by Oden RV. *Anesthesiol Clin North Am* 1989; 7:193-210

45. Sandler AN, Baxter AD, Katz J, Samson B, Friedlander M, Norman P, Koren G, Roger S, Hull K, Klein J: A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory and pharmacokinetic effects. *ANESTHESIOLOGY* 1994; 81:1169-80

46. Catling JA, Pinto DM, Jordan C, Jones JG: Respiratory effects of analgesia after cholecystectomy: Comparison of continuous and intermittent papaveretum. *BMJ* 1980; 281:478-80

47. Catley DM, Thornton C, Jordan C, Lehane JR, Royston D, Jones JG: Pronounced episodic oxygen desaturation in the postoperative period: Its association with ventilatory pattern and analgesic regimen. *ANESTHESIOLOGY* 1985; 63:20-8

48. Mather LE, Owen H: The scientific basis of patient-controlled analgesia. *Anesth Intens Care* 1988; 16:427-47

49. Duthie DJR, Rowbotham DJ, Wyld R, Henderson PD, Nimmo WS: Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. *Br J Anaesth* 1988; 60:614-8

50. Holley FO, Van Steennis C: Postoperative analgesia with fentanyl: Pharmacokinetics and pharmacodynamics of constant-rate iv and transdermal delivery. *Br J Anaesth* 1988; 60:608-13

51. Bernard JM, Lagarde D, Souron R: Balanced postoperative analgesia: Effect of intravenous clonidine on blood gases and pharmacokinetics of intravenous fentanyl. *Anesth Analg* 1994; 79:1126-32

52. Guinard JP, Mavrocordatos P, Chiolero R, Carpenter RL: A randomized comparison of intravenous versus lumbar and thoracic epidural fentanyl for analgesia after thoracotomy. *ANESTHESIOLOGY* 1992; 77:1108-15

53. White WD, Pearce DJ, Norman J: Postoperative analgesia: A comparison of intravenous on-demand fentanyl with epidural bupivacaine. *BMJ* 1979; 2:166-7

54. Rosenberg PH, Heino A, Scheinin B: Comparison of intramuscular analgesia, intercostal block, epidural morphine and on-demand i.v. fentanyl in the control of pain after upper abdominal surgery. *Acta Anaesthesiol Scand* 1984; 28:603-7

55. Grant RP, Dolman JF, Harper JA, White SA, Parsons DG, Evans KG, Merrick PC: Patient-controlled lumbar epidural fentanyl compared with patient-controlled intravenous fentanyl for post-thoracotomy pain. *Can J Anaesth* 1992; 39:214-9

56. Kay B: Postoperative pain relief. Use of an on-demand analgesia computer (ODAC) and a comparison of the rate of use of fentanyl and alfentanil. *Anaesthesia* 1981; 36:949-51

57. Welch EA, Breen DP: Patient-controlled on-demand epidural fentanyl. A comparison of patient-controlled on-demand fentanyl delivered epidurally or intravenously. *Anaesthesia* 1991; 46:438-41

58. Lehmann KA, Grond S, Freier J, Zech D: Postoperative pain management and respiratory depression after thoracotomy: A comparison of intramuscular piritramide and intravenous patient-controlled analgesia using fentanyl or buprenorphine. *J Clin Anesth* 1991; 3:194-201

59. Lehmann KA: Patient-controlled intravenous analgesia for postoperative pain relief. *Advances in Pain Research and Therapy*. Vol. 18. Edited by Max M, Portenoy R, Laska E. New York, Raven Press, 1991, pp 481-506

60. Howell PR, Gambling DR, Pavy T, McMorland G, Douglas MJ: Patient-controlled analgesia following Caesarean section under general anaesthesia: A comparison of fentanyl with morphine. *Can J Anaesth* 1995; 42:41-5

61. Ginsberg B, Gil KM, Muir M, Sullivan F, Williams DA, Glass PSA: The influence of lockout intervals and drug selection on patient-controlled analgesia following gynecological surgery. *Pain* 1995; 62:95-100

62. Woodhouse A, Hobbes AFT, Mather LE, Gibson M: A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment. *Pain* 1996; 64:115-21

63. Lehmann KA, Einnolf C, Eberlein HJ, Nagel R: Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia. *Eur J Clin Pharmacol* 1991; 41:17-21

64. Welch EA: On-demand analgesia. A double-blind comparison of on-demand intravenous fentanyl with regular intramuscular morphine. *Anaesthesia* 1983; 38:19-25

65. Laitinen J, Nuutinen L: Intravenous diclofenac coupled with PCA fentanyl for pain relief after total hip replacement. *ANESTHESIOLOGY* 1992; 76:194-8

66. Suttman H, Juhl G, Florian W, Dworzak H, Ebentheuer H: Patientenkontrollierte analgesie. Eine technische spielerei oder eine bereicherung der schmerztherapie? *Anaesthesist* 1988; 37:543-50

67. Cooper DW, Ryall DM, Desira WR: Extradural fentanyl for postoperative analgesia: Predominant spinal or systemic action? *Br J Anaesth* 1995; 74:184-7

68. Scott JC, Cooke JE, Stanski DR: Electroencephalographic quantification of opioid effect. Comparative pharmacodynamics of fentanyl and sufentanil. *ANESTHESIOLOGY* 1991; 74:34-42

69. Lehmann KA: Practical experience with demand analgesia for postoperative pain. *Patient-Controlled Analgesia*. 1st edition. Edited by Harmer M, Rosen M, Vickers MD. Blackwell, Oxford, 1985, pp 134-9

70. Lehmann KA: The pharmacokinetics of opioid analgesics. Discussion, *Patient-Controlled Analgesia*. 1st edition. Edited by Harmer M, Rosen M, Vickers MD. Blackwell, Oxford, 1985, pp 18-29

71. Hansen LA, Noyes MA, Lehman ME: Evaluation of patient-controlled analgesia (PCA) versus PCA plus continuous infusion in postoperative cancer patients. *J Pain Symptom Manage* 1991; 6:4-14

72. Owen H, Szekely SM, Plummer JL, Cushnie JM, Mather LE: Variables of patient-controlled analgesia. 2. Concurrent infusion. *Anaesthesia* 1989; 44:11-3

73. Parker RK, Holtmann B, White PF: Patient-controlled analgesia: Does a concurrent opioid infusion improve pain management after surgery? *JAMA* 1991; 266:1947-52

74. Parker RK, Holtmann B, White PF: Effects of a night-time opioid infusion with PCA therapy on patient comfort and analgesic requirements after abdominal hysterectomy. *ANESTHESIOLOGY* 1992; 76:362-7

75. Wu MYC, Purcell GC: Patient-controlled analgesia: The value of a background infusion (letter). *Anaesth Intensive Care* 1990; 18:575-6

76. Fleming BM, Coombs DW: A survey of complications documented in a quality-control analysis of patient-controlled analgesia in the postoperative patient. *J Pain Symptom Manage* 1992; 7:463-9

77. Notcutt WG, Morgan RJM: Introducing patient-controlled analgesia for postoperative pain control into a district general hospital. *Anaesthesia* 1990; 45:401-6

78. Etches RC: Respiratory depression associated with patient-controlled analgesia: A review of eight cases. *Can J Anaesth* 1994; 41:125-31

79. McLesky CH: Fentanyl TTS for postoperative analgesia. *Eur J Pain* 1990; 11:92-7

80. Hill HF: Clinical pharmacology of transdermal fentanyl. *Eur J Pain* 1990; 11:81-91

## FENTANYL AND ACUTE PAIN MANAGEMENT

81. Tarver SD, Stanley TH: Alternative routes of drug administration and new drug delivery systems, *Advances in Anesthesia*. Vol. 7. Edited by Stoelting RK, Barash P, Gallagher TJ. Chicago, Year Book Medical Publishers, 1990, pp 337-67
82. Latasch L, Luders S: Transdermal fentanyl against postoperative pain. *Acta Anaesthesiol Belg* 1989; 40:113-9
83. Plezia PM, Kramer TH, Linford J, Hameroff SR: Transdermal fentanyl: Pharmacokinetics and preliminary clinical evaluation. *Pharmacotherapy* 1989; 9:2-9
84. Caplan RA, Ready LB, Oden RV, Matsen FA, Nessly ML, Olsson GL: Transdermal fentanyl for postoperative pain management. A double-blind placebo study. *JAMA* 1989; 261:1036-9
85. Von Bormann B, Ratthey K, Schwetlick G, Schneider C, Muller H, Hempelman G: Postoperative Schmerztherapie durch transdermales Fentanyl. *Anesth Intensivther Notfallmed* 1988; 23:3-8
86. Rowbotham DJ, Wyld R, Peacock JE, Duthie DJR, Nimmo WS: Transdermal fentanyl for the relief of pain after abdominal surgery. *Br J Anaesth* 1989; 63:56-9
87. Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Szekely S, Mather LE, Owen H, Cousins MJ: The efficacy of transdermal fentanyl in the treatment of postoperative pain: A double-blind comparison of fentanyl and placebo systems. *Pain* 1990; 40:21-8
88. Van Bastelaere M, Rolly G, Abdullah NM: Postoperative analgesia and plasma levels after transdermal fentanyl for orthopedic surgery: Double-blind comparison with placebo. *J Clin Anesth* 1995; 7:26-30
89. Broome IJ, Wright BM, Bower S, Reilly CS: Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. *Anesthesia* 1995; 50:300-3
90. Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Gaukroger P, Cousins MJ: The transdermal administration of fentanyl in the treatment of postoperative pain: Pharmacokinetics and pharmacodynamic effects. *Pain* 1989; 37:193-202
91. Sevarino FB, Naulty JS, Sinatra R, Chin ML, Paige D, Conry K, Silverman DG: Transdermal fentanyl for postoperative pain management in patients recovering from abdominal gynecologic surgery. *ANESTHESIOLOGY* 1992; 77:463-6
92. Bell SD, Goldberg ME: Comparison of single patch multi-day vs multiple patch single-day TTS fentanyl. *Can J Anaesth* 1989; 36:S116
93. Miguel R, Kreitzer JM, Reinhart D, Sebel PS, Bowie J, Freedman G, Eisenkraft JB: Postoperative pain control with a new transdermal fentanyl delivery system. *ANESTHESIOLOGY* 1995; 83:470-7
94. Bernstein KJ, Klausner MA: Potential dangers related to transdermal fentanyl (Duragesic®) when used for postoperative pain (Letter). *Dis Colon Rectum* 1994; 37:1339-40
95. Sandler A: Transdermal fentanyl: Acute analgesic studies. *J Pain Symptom Manage* 1992; 7:S27-S35
96. Bertolucci LE: Introduction of antiinflammatory drugs by iontophoresis: Double blind study. *J Orthop Sports Phys Ther* 1982; 4:103-8
97. Glass JM, Stephen RL, Jacobson SC: The quantity and distribution of radiolabeled dexamethasone delivered to tissue by iontophoresis. *Int J Dermatol* 1980; 19:519-25
98. Bezzant JL, Stephen RL, Petelenz TJ, Jacobsen SC: Painless cauterization of spider veins with the use of iontophoretic local anesthesia. *J Am Acad Dermatol* 1988; 19:869-75
99. Ashburn MA, Stephen RL, Ackerman E, Petelenz TJ, Hare B, Pace NL, Hofman AA: Iontophoretic delivery of morphine for postoperative analgesia. *J Pain Symptom Manage* 1992; 7:27-33
100. Ashburn MA, Streisand J, Zhang J, Love G, Rowin M, Niu S, Kievit JK, Kroep JR, Mertens MJ: The iontophoresis of fentanyl citrate in humans. *ANESTHESIOLOGY* 1995; 82:1146-53
101. Ashburn MA, Lind GH, Gillie MH, de Boer AJF, Pace NL, Stanley TH: Oral transmucosal fentanyl citrate (OTFC) for the treatment of postoperative pain. *Anesth Analg* 1993; 76:377-81
102. Striebel HW, Pommerening J, Rieger A: Intranasal fentanyl titration for postoperative pain management in an unselected population. *Anaesthesia* 1993; 48:753-7
103. Stanley TH, Leiman BC, Rawal N, Marcus MA: The effects of oral transmucosal fentanyl citrate premedication on preoperative behavioural responses and gastric volume and acidity in children. *Anesth Analg* 1989; 69:328-35
104. Ashburn MA, Streisand JB, Tarver SD, Mears SL, Mulder SM, Floet AW, Luijendijk RW, Elwyn RA, Pace NL, Stanley TH: Oral transmucosal fentanyl citrate for premedication in paediatric outpatients. *Can J Anaesth* 1990; 37:857-66
105. Nelson PS, Streisand, Mulder SM: Comparison of oral transmucosal fentanyl citrate and an oral solution of meperidine, diazepam and atropine for premedication in children. *ANESTHESIOLOGY* 1989; 70:616-21
106. Streisand JB, Stanley TH, Hague B: Oral transmucosal fentanyl citrate premedication in children. *Anesth Analg* 1989; 69:28-34
107. Feld LH, Champeau MW, van Steenis CA: Preanesthetic medication in children: A comparison of oral transmucosal fentanyl citrate versus placebo. *ANESTHESIOLOGY* 1989; 71:374-7
108. Stanley TH, Hague B, Mock DL: Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers. *Anesth Analg* 1989; 69:21-7
109. Streisand JB, Varvel JR, Stanski DR, Le Maire L, Ashburn MA, Hague BI, Tarver SD, Stanley TH: Absorption and bioavailability of oral transmucosal fentanyl citrate. *ANESTHESIOLOGY* 1991; 75:223-9
110. Sevarino FB, Ginsberg B, Lichter JL, Joshi GP, Nordbrock E, Busch MA: Oral transmucosal fentanyl citrate (OTFC) compared with IV morphine for acute pain in patients following abdominal surgery. *Anesth Analg* 1997; 84:S330
111. Bende M, Flisberg K, Larsson E: A method for determination of blood flow with <sup>133</sup>Xe in human nasal mucosa. *Acta Otolaryngol* 1983; 96:277-85
112. Hussain A, Foster T, Hirai S, Kashihara T, Batenhorst R, Jones M: Nasal absorption of propranolol in humans (letter). *J Pharm Sci* 1980; 69:1240
113. Striebel HW, Koenigs D, Krämer J: Postoperative pain management by intranasal demand-adapted fentanyl titration. *ANESTHESIOLOGY* 1992; 77:281-5
114. Chrubasik J, Wust H, Friedrich G, Geller E: Absorption and bioavailability of nebulized morphine. *Br J Anaesth* 1988; 61:228-30
115. Masters NJ, Bennet MRD, Wedley JR: Nebulised morphine: A new delivery method for pain relief. *Practitioner* 1985; 229:649-53
116. Worsley MH, Macleod AD, Brodie MJ, Asbury AJ, Clark C: Inhaled fentanyl as a method of analgesia. *Anaesthesia* 1990; 45:449-51
117. Higgins MJ, Asbury AJ, Brodie MJ: Inhaled nebulized fentanyl for post-operative analgesia. *Anaesthesia* 1991; 46:973-6
118. Bangham AD, Standish MM, Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. *J Mol Biol* 1965; 13:238-52
119. Hung OR, Whynot SC, Varvel JR, Shafer SL, Mezei M: Pharmacokinetics of inhaled liposome-encapsulated fentanyl. *ANESTHESIOLOGY* 1995; 83:277-84

120. Hung OR, Coonan E, Whynot SC, Mezei M: Pharmacokinetics of multiple doses of inhaled liposomal-encapsulated fentanyl (LEF) in healthy volunteers (abstract). *Can J Anaesth* 1997; 44:A47B
121. Tattersfield AE: Bronchodilators in the prevention of asthma, Bronchodilator Therapy. Edited by Clark TJH. Auckland, New Zealand, ADIS, 1984, pp 76-92
122. Moore RA, Bullingham RSJ, McQuay HJ, Hand CW, Aspel JB, Allen MC, Thomas D: Dural permeability to narcotics: In vitro determination and application to extradural administration. *Br J Anaesth* 1982; 54:1117-28
123. Bernards CM, Hill HF: Physical and chemical properties of drug molecules governing their diffusion through the spinal meninges. *ANESTHESIOLOGY* 1992; 77:750-6
124. Sandler AN: Clinical pharmacology and practical applications of spinal opioids, *The Pharmacological Basis of Anesthesiology: Basic Science and Practical Applications*. Edited by Bowdle TA, Horita A, Kharasch ED. New York, Churchill Livingstone, 1994, pp 149-78
125. Gourlay GK, Murphy TM, Plummer JL, Kowalski SR, Cherry DA, Cousins MJ: Pharmacokinetics of fentanyl in lumbar and cervical CSF following lumbar epidural and intravenous administration. *Pain* 1989; 38:253-9
126. Coda BA, Brown MC, Schaffer R, Donaldson G, Jacobson R, Hautman B, Shen DD: Pharmacology of epidural fentanyl, alfentanil, and sufentanil in volunteers. *ANESTHESIOLOGY* 1994; 81:1149-61
127. Lomessy A, Magnin C, Viale JP, Motin J, Cohen R: Clinical advantages of fentanyl given epidurally for postoperative analgesia. *ANESTHESIOLOGY* 1984; 61:466-9
128. Gough JD, Williams AB, Vaughan RS, Khalil JF, Butchart EG: The control of post-thoracotomy pain. A comparative evaluation of thoracic epidural fentanyl infusions and cryo-analgesia. *Anaesthesia* 1988; 43:780-3
129. Renaud B, Brichant JF, Clergue F, Chauvin M, Levron JC, Viars P: Ventilatory effects of continuous epidural infusion of fentanyl. *Anesth Analg* 1988; 67:971-5
130. Badner NH, Sandler AN, Koren G, Lawson SL, Klein J, Einarson TR: Lumbar epidural fentanyl infusions for post-thoracotomy patients: Analgesic, respiratory, and pharmacokinetic effects. *J Cardiothorac Anesth* 1990; 4:543-51
131. Sawchuk CWT, Ong B, Unruh HW, Horan TA, Greengrass R: Thoracic versus lumbar epidural fentanyl for postthoracotomy pain. *Ann Thor Surg* 1993; 55:1472-6
132. Baron CM, Kowalski SE, Greengrass R, Horan TA, Unruh HW, Baron CL: Epinephrine decreases postoperative requirements for continuous thoracic epidural fentanyl infusions. *Anesth Analg* 1996; 82:760-5
133. Collins JG, Matsumoto M, Kitahata LM: Suppression by spinally administered epinephrine of noxiously evoked dorsal horn neuron activity in cats. Evidence for spinal epinephrine analgesia. *Anesth Analg* 1983; 62:253-4
134. Gourlay GK, Cherry DA, Cousins MJ: Cephalad migration of morphine in CSF following lumbar epidural administration in patients with cancer pain. *Pain* 1985; 23:317-26
135. Gourlay GK, Cherry DA, Plummer JL, Armstrong PJ, Cousins MJ: The influence of drug polarity on the absorption of opioid drugs into CSF and subsequent cephalad migration following lumbar epidural administration: Application to morphine and pethidine. *Pain* 1987; 31:297-305
136. McQuay HJ, Sullivan AF, Smallman K, Dickenson AH: Intrathecal opioids, potency and lipophilicity. *Pain* 1989; 36:111-5
137. Guinard JP, Chiolero R, Mavrocordatos P, Carpenter RL: Prolonged intrathecal fentanyl analgesia via 32-gauge catheters after thoracotomy. *Anesth Analg* 1993; 77:936-41
138. Etches R, Sandler AN, Daley MD: Respiratory depression and spinal opioids. *Can J Anaesth* 1989; 36:165-85
139. Weightman WM: Respiratory arrest during fentanyl infusion of bupivacaine and fentanyl. *Anesth Intens Care* 1991; 19:282-4
140. White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC: Side effects during continuous epidural infusion of morphine and fentanyl. *Can J Anaesth* 1992; 39:576-82
141. Shipton EA: Pruritus—A side effect of epidural fentanyl for postoperative analgesia. *S Afr Med J* 1984; 66:61-2
142. Mackersie RC, Shackford SR, Hoyt DB, Karagianes TG: Continuous epidural fentanyl analgesia: Ventilatory function improvement with routine treatment of blunt chest injury. *J Trauma* 1987; 27:1207-12
143. Rutter DV, Skewes DG, Morgan M: Extradural opioids for postoperative analgesia. A double-blind comparison of pethidine, fentanyl and morphine. *Br J Anaesth* 1981; 53:915-9
144. Geller E, Chrubasik J, Graf R, Chrubasik S, Schulte-Mönting J: A randomized double-blind comparison of epidural sufentanil versus intravenous sufentanil or epidural fentanyl analgesia after major abdominal surgery. *Anesth Analg* 1993; 76:1243-50
145. Welchew EA, Thornton JA: Continuous thoracic epidural fentanyl. A comparison of epidural fentanyl with intramuscular papaverum for postoperative pain. *Anaesthesia* 1982; 37:309-16
146. Chrubasik J, Wust H, Schulte-Mönting J, Thon K, Zindler M: Relative analgesic potency of epidural fentanyl, alfentanil, and morphine in the treatment of postoperative pain. *ANESTHESIOLOGY* 1988; 68:929-33
147. Owen H, Kluger MT, Ilesley AH, Baldwin AM, Fronsco RRL, Plummer JL: The effect of fentanyl administered epidurally by patient-controlled analgesia, continuous infusion, or a combined technique of oxyhemoglobin saturation after abdominal surgery. *Anaesthesia* 1993; 48:20-5
148. Naulty JS, Datta S, Ostheimer GW, Johnson MD, Burger GA: Epidural fentanyl for postcesarean delivery pain management. *ANESTHESIOLOGY* 1985; 63:694-8
149. Coe A, Sarginson R, Smith MW, Donnelly RJ, Russell GN: Pain following thoracotomy. A randomised, double-blind comparison of lumbar versus thoracic epidural fentanyl. *Anaesthesia* 1991; 46:918-21
150. Baxter AD, Laganière S, Samson B, Stewart J, Hull K, Goernert J: A comparison of lumbar epidural and intravenous fentanyl infusions for post-thoracotomy analgesia. *Can J Anaesth* 1994; 41:184-91
151. Melendez JA, Cirella VN, Delphin ES: Lumbar epidural fentanyl analgesia after thoracic surgery. *J Cardiothorac Anesth* 1989; 3:150-3
152. Benzon HT, Wong HY, Belavic AM, Goodman I, Mitchell D, Lefheit T, Locicero J: A randomized double-blind comparison of epidural fentanyl infusion versus patient-controlled analgesia with morphine for postthoracotomy pain. *Anesth Analg* 1993; 76:316-22
153. Thomson CA, Becker DR, Messick JM, de Castro MA, Pairolero PC, Trastek VF, Murray MJ, Schulte NK, Offord KP, Ferguson JA: Analgesia after thoracotomy: Effects of epidural fentanyl concentration/infusion rate. *Anesth Analg* 1995; 81:973-81
154. Grass JA, Sakima NT, Valley M, Fischer K, Jackson C, Walsh P, Bourke DL: Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. *ANESTHESIOLOGY* 1993; 78:642-8

## FENTANYL AND ACUTE PAIN MANAGEMENT

155. Birnbach DJ, Johnson MD, Arcario T, Datta S, Naulty JS, Osheimer GW: Effect of diluent volume on analgesia produced by epidural fentanyl. *Anesth Analg* 1989; 68:808-10
156. Torda TA, Pybus DA: Comparison of four narcotic analgesics for extradural analgesia. *Br J Anaesth* 1982; 54:291-4
157. Pierrot M, Blaise M, Dupuy A, Hugon S, Cupa M: Analgésie péridurale à dose élevée de fentanyl: Échec de la méthode pour la kinésithérapie post-opératoire précoce avec chirurgie du genou. *Can Anaesth Soc J* 1982; 29:587-92
158. Welch EA: The optimum concentration for epidural fentanyl. A randomised, double-blind comparison with and without 1:200,000 adrenaline. *Anaesthesia* 1983; 38:1037-41
159. Yu PYH, Gambling DR: A comparative study of patient-controlled epidural fentanyl and single dose epidural morphine for post-Caesarean analgesia. *Can J Anaesth* 1993; 40:416-20
160. Bouchard F, Drolet P: Thoracic versus lumbar administration of fentanyl using patient-controlled epidural after thoracotomy. *Reg Anesth* 1995; 20:385-8
161. Cooper DW, Turner G: Patient-controlled extradural analgesia to compare bupivacaine, fentanyl and bupivacaine with fentanyl in the treatment of postoperative pain. *Br J Anaesth* 1993; 70:503-7
162. Loan WB, Morrison JD: The incidence and severity of postoperative pain. *Br J Anaesth* 1967; 39:695-8
163. Sudarshan G, Browne BL, Matthews JNS, Conacher ID: Intrathecal fentanyl for post-thoracotomy pain. *Br J Anaesth* 1995; 75:19-22
164. Ballantyne JC, Loach AB, Carr DB: Itching after epidural and spinal opiates. *Pain* 1988; 33:149-60
165. Morgan M: The rationale use of intrathecal and extradural opioids. *Br J Anaesth* 1989; 63:165-88
166. Chaney MA: Side effects of intrathecal and epidural opioids. *Can J Anaesth* 1995; 42:891-903
167. Robertson K, Douglas MJ, McMorland GH: Epidural fentanyl, with and without epinephrine for post-Caesarean section analgesia. *Can Anaesth Soc J* 1985; 32:502-5
168. Allaire PH, Messick JM, Oesterling JE, Byer DE, Myers RP, Lieber MM, Chantigian RC, Welna JO, Patterson DE, Blute ML, Offord KP, Ferguson JA: A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy. *Mayo Clin Proc* 1992; 67:1031-41
169. Rawal N, Möllefors K, Axelsson K, Lingårdh G, Widman B: An experimental study of urodynamic effects of epidural morphine and of naloxone reversal. *Anesth Analg* 1983; 62:641-7
170. Dray A, Metsch R: Spinal opioid receptors and inhibition of urinary bladder motility in vivo. *Neurosci Lett* 1984; 47:81-4
171. Drenger B, Magora F, Evron S, Caine M: The action of intrathecal morphine and methadone on the lower urinary tract in the dog. *J Urol* 1986; 135:852-5
172. Chrubasik J, Chrubasik S, Mather L: *Postoperative Epidural Opioids*. 1st edition. Heidelberg, Springer-Verlag, 1993, pp 25-42
173. Chrubasik J, Chrubasik S, Black A: Respiratory depression after extradural fentanyl. *Br J Anaesth* 1993; 71:164-5
174. Chisholm RH, Fleischl J: Respiratory arrest with epidural fentanyl (Letter). *Anaesth Int Care* 1990; 18:423
175. Wells DG, Davies G: Profound central nervous system depression from epidural fentanyl for extracorporeal shock wave lithotripsy. *ANESTHESIOLOGY* 1987; 67:991-2
176. Brockway MS, Noble DW, Sharwood-Smith GH, McClure JH: Profound respiratory depression after extradural fentanyl. *Br J Anaesth* 1990; 64:243-5
177. Noble DW, Morrison LM, Brockway MS, McClure JH: Adrenaline, fentanyl or adrenaline and fentanyl as adjuncts to bupivacaine for extradural anaesthesia in elective caesarean section. *Br J Anaesth* 1991; 66:645-50
178. Wang CY: Respiratory depression after extradural fentanyl (Letter). *Br J Anaesth* 1992; 69:544
179. Ahuja BR, Strunin L: Respiratory effects of epidural fentanyl. *Anaesthesia* 1985; 40:949-55
180. Hunt CO, Naulty JS, Bader AM, Hauch MA, Vartikar JV, Datta S, Hertwig LM, Ostheimer GW: Perioperative analgesia with subarachnoid fentanyl-bupivacaine for cesarean delivery. *ANESTHESIOLOGY* 1989; 71:535-40
181. Belzarena SD: Clinical effects of intrathecally administered fentanyl in patients undergoing cesarean section. *Anesth Analg* 1992; 74:653-7
182. Domsy M, Tarantino D: Patient-controlled spinal analgesia for postoperative pain control. *Anesth Analg* 1992; 75:453-5
183. Jacobson L, Chabal C: Prolonged relief of acute postamputation phantom limb pain with intrathecal fentanyl and epidural morphine. *ANESTHESIOLOGY* 1989; 71:984-5
184. Tobias JD: Continuous intrathecal fentanyl infusion for postoperative analgesia. *J Pain Symptom Management* 1991; 6:481-3
185. Reuben SS, Dunn SM, Duprat KM, O'Sullivan P: An intrathecal fentanyl dose-response study in lower extremity revascularization procedures. *ANESTHESIOLOGY* 1994; 81:1371-5
186. Jacobson L, Chabal C, Brody MC, Mariano AJ, Chaney EF: A comparison of the effects of intrathecal fentanyl and lidocaine on established postamputation stump pain. *Pain* 1990; 40:137-41
187. Niemi L, Pitkänen MT, Tuominen MK, Rosenberg PH: Comparison of intrathecal fentanyl infusion with intrathecal morphine infusion or bolus for postoperative pain relief after hip arthroplasty. *Anesth Analg* 1993; 77:126-30
188. Honet JE, Arkoosh VA, Norris MC, Huffnagle HJ, Silverman NS, Leighton BL: Comparison among intrathecal fentanyl, meperidine, and sufentanil for labor analgesia. *Anesth Analg* 1992; 75:734-9
189. Murphy MR: *Opioids, Clinical Anaesthesia*. 2nd edition. Edited by Barash PG, Cullen BF, Stoelting RK. Philadelphia, JB Lippincott, 1992, pp 413-38
190. Inturrisi CE, Colburn WA: Application of pharmacokinetic-pharmacodynamic modelling to analgesia, *Advances in Pain Research and Therapy*. Vol. 8. Edited by Foley KM, Inturrisi CE. New York, Raven Press, 1986, pp 441-52
191. Carrie LES, O'Sullivan GM, Seegobin R: Epidural fentanyl in labour. *Anaesthesia* 1981; 36:965-9
192. Kreitzer JM, Kirschenbaum LP, Eisenkraft JB: Epidural fentanyl by continuous infusion for relief of postoperative pain. *Clin J Pain* 1989; 5:283-90
193. Salomäki TE, Laitinen Jo, Vainionpää V, Nuutinen LS: 0.1% Bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. *Reg Anesth* 1995; 20:435-43
194. Joshi GP, McCarroll SM, O'Rourke K: Postoperative analgesia after lumbar laminectomy: Epidural fentanyl infusion versus patient-controlled intravenous morphine. *Anesth Analg* 1995; 80:511-4
195. Hannallah RS, Broadman LM, Belman AB, Abramowitz MD, Epstein BS: Comparison of caudal and ilioinguinal/iliohypogastric nerve blocks for control of post-orchiopey pain in pediatric ambulatory surgery. *ANESTHESIOLOGY* 1987; 66:832-4